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Cancer places a considerable burden on patients’ health-related quality of life (HRQOL). 
Information on own disease can both help patients to cope with symptoms and side-effects, 
and make them more competent participants in shared decision-making with clinicians. In 
this context the Center for Shared Decision Making and Nursing Research developed a 
tailored Internet support system called WebChoice. This thesis is a partial economic 
evaluation of the effects of WebChoice, where its impact on HRQOL is explored. 
Methods 
The research team randomised breast cancer and prostate cancer patients into two groups, a 
WebChoice group and a control group. The patients’ HRQOL was measured three times 
during the intervention period of one year. HRQOL weights were measured with the multi 
attribute health status classification system, 15D. This thesis measures the health outcome 
and WebChoice effects by statistical methods. The health outcome was measured in quality 
adjusted life years (QALYs). Data were analysed with t-tests and multiple linear regressions. 
Results 
In total, 445 patients were recruited and randomised to WebChoice groups or control groups. 
This thesis presents data for 234 patients who filled in the 15D questionnaire at baseline, at 6 
months and at 12 months. Among 130 breast cancer patients included in this study, the mean 
15D score at baseline was 0.85 in the WebChoice group and 0.88 in the control group, while 
the respective means were 0.85 and 0.88 by the end of the trial. Among 104 prostate cancer 
patients included in this study, the mean 15D score at baseline was 0.87 in the WebChoice 
group and 0.87 in the control group, while the respective means were 0.84 and 0.84 by the 
end of the trial. Adjusted for baseline 15D, the mean QALYs gained for WebChoice 
compared to the control group, was -0.03 for the breast cancer group and -0.01 for the 
prostate cancer group. HRQOL score at baseline was the only variable which had a 
significant impact on this result.  
Interpretation/conclusion 
The results of this study indicate that WebChoice has no impact on HRQOL for breast 
cancer and prostate cancer patients. However, the conclusion must be made with the 
following reservations: The result does not necessarily apply to patients with a recent 
diagnosis, or with little education or with a low HRQOL.    
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1.1 Shared decision-making 
Physicians have been seen as paternalistic in their professional conduct, making decisions 
with great consequences without involving the patient’s values (Wulff et al., 2001). A 
traditional paternalistic view is that the physicians are the only ones who know what is best 
for the patient. A consequence is that historically, patients have only to a limited extent been 
involved in the decision-making process. More recently, shared decision-making has been 
introduced. This decision type is a different way of thinking about how clinicians, and 
especially physicians, should communicate with patients and approach treatment options. 
The following definition of shared decision making has been proposed by the 
Department of Biomedical Informatics at the Colombia University:  
[I]nvolvement of patients with their providers in making health care decisions that are informed 
by the best available evidence about treatment / screening / illness management options, potential 
benefits, and harms, and that consider patient preferences (Patient preferences in Health Care 
Decision Making. Shared Decision Making, 2009). 
Shared decision-making is present when the patient together with the physicians and other 
clinicians make informed decisions about the patient’s health care. The main arguments for 
introducing shared decision-making are autonomy and patient preferences. Patient autonomy 
in a treatment perspective can be viewed as a fundamental right to decide over one’s own 
health. The extent of autonomy is an ethical question and beyond the scope of this thesis. 
Patient autonomy and patient preferences are two sides of the same matter. In an ever 
growing arsenal of treatment options with radically different consequences, it is impossible 
for the physician to decide the “best” option (Hunink & Glasziou, 2001). The “impossibility” 
is not in terms of complex professional evaluation, but more in terms the patients’ wide array 
of preferences. The physician can simply not decide what treatment (with its consequences) 
is best for the particular patient without having detailed information about the patient’s 
preferences. Patient autonomy implies that patients are best suited to value process and 
outcome from diagnostics and treatments. 
Although the patient’s own views and values are crucial in the choice of diagnostics 
and treatment, the patient must still have the option to leave the decision to the clinician. For 
instance, clinical experience indicates that young and/or relatively healthy patients want to 
take great part in the decisions, while older and/or sicker patients often prefer to leave 
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decisions to the physician (Hunink & Glasziou, 2001). However, shared decision-making 
still implies that physicians should base their decisions on the patient’s preferences.  
A premise for shared decision-making is that the patient has received information 
relevant to the decision he or she is about to make. It is the clinicians’ (especially the 
physicians’ and nurses’) task to ensure that the patient gets reliable and up-to-date 
information about the specific disease he or she suffers from and the different treatment 
options. Internet support, both tailored and general, have proven valuable for informing 
patients and thereby making them better qualified to take part in a shared decision-making 
process (Brennan et al., 2001, Fleischer et al., 2002 and Gustafson et al., 1999 & 2001). 
Shared decision making can improve health-related quality of life (HRQOL), as 
HRQOL is sensitive to the patient’s preferences. HRQOL will be discussed later. Even 
though there has been limited focus on the practice of shared decision making in Norway, 
the principles do apply. This master thesis will explore the consequences of one of the 
aspects in shared decision-making: Information provided through tailored Internet support 
and its effect on cancer patients’ HRQOL.  
In the following, I will first describe two types of cancer and their potential 
consequences for HRQOL. Subsequently, the concept of health-related quality of life and 
how it can be measured will be explored. The thesis will then describe a clinical trial of 
tailored Internet support to enhance shared decision-making, and test empirically whether it 
influences cancer patients’ HRQOL.  
1.2 Cancer 
1.2.1 The cell 
The cell is the principle building unit of the human body. There are different types of cells, 
and similar types of cells together make up one type of tissue. The main types of tissues are 
epithelium tissue, muscle tissue, connective tissue, nerve tissue and liquid tissue (Bjålie et 
al., 1998). Every cell consists of cytoplasm, a liquid inside the cell, surrounded by a cell 
membrane. In the cytoplasm there are different types of cell organelles, and in the centre of 
most cells is the nucleus which “administrates” the protein synthesis. The nucleus contains 
DNA molecules which store genetic information. The DNA governs the production of 
proteins.  
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Figure 1: The cell 
Description:  
1. Nucleolus  
2. Nucleus  
3. Ribosome  
4. Vesicle  
5. Rough endoplasmic reticulum  
6. Golgi apparatus (or "Golgi body")  
7. Cytoskeleton  
8. Smooth endoplasmic reticulum  
9. Mitochondrion  
10. Vacuole  
11. Cytosol  
12. Lysosome  
13. Centriole 
Illustration “biological_cell_svg” with explanation, is from Wikipedia.org, and used with permission under a 
Creative Commons licence. 
Each DNA molecule consists of two nucleotide chains which are coiled up beside each 
other. The two nucleotide chains are linked through hydrogen connections. The chains 
consist of single nucleotides, and each nucleotide consists of a monosaccharide, a phosphate 
group and a nitrogen base. There are four different nitrogen bases: Adenine (A), guanine 
(G), cytosine (C) and thymine (T), and each nucleotide consist of a combination of two 
bases. The sequence of nucleotides in the DNA-chain represents the genetic information, in 
other words the genetic code. Three nucleotides in a row, a triplet, decide one type of amino 
acid. A gene contains the number of triplets (or the number of amino acids) which is 
necessary to code for a specific protein.  
Figure 2: The DNA double helix 
 
The illustration “DNA overview.png” by Michael Ströck is from Wikipedia.org, used with permission under a GNU 
Free Documentation Licence. 
The human body grows and is maintained through cell growth. The cell itself grows until a 
certain point where it starts the process of dividing, a process which is called mitosis. The 
first step in mitosis is that all DNA in the nucleus is replicated. During the division process, 
one set of DNA is transferred to each of the two new cells with identical DNA. When the 
DNA is replicated, on special occasions an error called a mutation occurs. Errors or 
mutations could be that a nitrogen base changes place, that nitrogen bases are exchanged or 
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that more nitrogen bases are added. The consequence of a mutation is that the new DNA 
contains the code for a new protein. Amino acid sequence changes could either be no change 
in the cell, change in the cell, but it cannot grow or that the cell dies. A factor that increases 
the probability of mutations is mutagens. The mutagens break down the chemical bindings in 
the DNA. This results in disturbance of the process of division of the cell and a possible 
change of the nucleotides. 
1.2.2 Cancer  
Cancer is a disease of the regulation of tissue growth (Cancer, 2009). The cells keep 
growing even though the stimulation, which started the growing process, is absent (Næss, 
2002). The cluster of cells that emerges is called a tumour. The reason for the abnormal 
growth of the cancer cells is alteration of the genes in the DNA of these cells (Cancer, 
2009). Because of this error, the cell is dividing independently of the bodies’ normal 
mechanisms for regulation (Næss, 2002). The change in the genes can occur at several 
levels, from mutation that affects only one DNA nucleotide, to loss or gain of one or more 
chromosomes (Cancer, 2009). The change in the genes in cancer cells are most often due to 
mutations or changes in the nucleotide sequence. The loss or gain of a chromosome because 
of an error in the mitosis can also be the cause of the development of cancer cells. 
Oncogenes and tumour suppressor genes affect the cell growth in opposite directions. 
Oncogenes promote cell growth and predispose for cancer. The genes alter the normal cell 
cycle regulation and make it possible for an uncontrolled growth of the cell. Oncogenes are 
usually dominant and promote the malignant phenotype of cancer cells. Cancer promoting 
oncogenes are always activated in a cancer cell. They give the cell new properties, which 
lead to abnormal growth such as hyperactivity, invasion of other tissue, the cell’s ability to 
grow in different locations consisting of different tissue, and so on.  
The tumour suppressor genes are genes that inhibit the growth of a cell, both its 
survival and the cell division. These genes are often disabled, when changes in cancer-
promotion genetic occur (DNA damage). The tumour suppressor genes are recessive.  
Cancer develops when the abnormal cells are growing rapidly and/or do not die, and 
when they infiltrate the surrounding tissue (Næss, 2002). Further, cancer spreads when the 
abnormal cells start to grow into the lymph vessels and veins, and are transported as 
satellites (metastases) to other areas of the body where they keep growing. The extent of 
cancer spread, including the number and location of metastases, represents the basis for 
staging of cancer diseases. 
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1.2.3 Breast cancer 
Breast cancer is the most frequent type of cancer for women in Norway, but men can also get 
the disease (Næss, 2002). For women below 20 years the disease is rare. In 2006,  2687 
(2673 women and 14 men) persons were diagnosed with the disease. The number of persons 
who died from it was 679 (675 women and 4 men) (Brystkreft, 2009 and Kreftstatistikk, 
2009). In 2006, no women between 0 to 14 years had the diagnosis breast cancer, while the 
numbers were 49 for women between 15 and 29 years, 4513 for women between 30 to 54 
years, 6245 for women between 55 to 74 and 2967 for women 75 years and older. This 
shows that the disease is nearly absent at ages below 30 years and that it increases with age.  
Most of the tumours in a breast arise from passage structures, while a few of the 
tumours arise from the milk glands. The tumours arising from the milk glands sometimes 
simultaneously arise in both breasts. The size of a tumour indicates the stage of the cancer. 
Normally, the smaller a tumour is when detected, the greater the chance is to survive from 
the cancer disease. A tumour in a woman’s breast can be detected by palpating the breast 
when it has reached a certain size (Næss, 2002). Another way to detect tumours is by 
mammography, which is an X-ray examination. With this technique or other imaging 
techniques smaller tumours can also be detected. The use of mammography has increased in 
recent years. Smaller tumours are therefore more frequently discovered today, but the impact 
of mammography screening on survival has been debated (Jørgensen et al., 2007). 
Symptoms 
Tumours at early stages are usually not painful and are therefore hard to detect without 
medical attention. Symptoms in addition to observable lumps are pain in the breast, eczema 
like outbreaks of the breast and suppuration from the breast.  
Staging 
For breast cancer the most used staging tool is the TNM system (T = primary tumour, N = 
regional nodes, M = distant metastasis) (Breast Cancer, 2009). The TNM system has four 
(five) main stages, where the first stage describes a condition where the breast cancer tumour 
shows no sign of invasion into other tissue or metastasis and the last stage describes a 
condition where the breast cancer has distant metastasis.  
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Table 1: Description of the TNM system for breast cancer (Breast cancer, 2009) 
Stage Description 
Stage 0 Carcinoma in situ 
Stage I Tumour (T) does not involve axillary lymph nodes (N) 
Stage II A Tumour of 2 to 5 centimetres in diameter and tumour does not involve axillary lymph nodes, or 
tumour of less than 2 centimetres in diameter and tumour involve initial axillary lymph node. 
Stage II B Tumours of more than 5 centimetres in diameter and tumour does not involve axillary lymph 
nodes, or tumour of 2 to 5 centimetres in diameter and tumour can involve as much as 4 
axillary lymph nodes 
Stage III A Tumour is either more than 5 centimetres in diameter and involves axillary lymph nodes, or 
tumour is from 2 to 5 centimetres and involves 4 or more axillary lymph nodes 
Stage III B Tumour has penetrated the chest wall or chest skin, and involve more than ten axillary lymph 
nodes 
Stage III C Tumour involve more than 10 axillary lymph nodes and one or more supraclavicular or 
infraclavicular lymph nodes are present, or initiary mammary lymph nodes 
Stage IV Distant metastasis 
There are more ways to stage breast cancer, however (Breast cancer, 2009). One 
classification system is based on hormone receptors. Two thirds of postmenopausal breast 
cancer tumours are progesterone receptor positive – PR+, and oestrogen receptor positive – 
ER+. Such breast cancers are sensitive to hormonal therapy. Another system is based on the 
presence or absence of human epidermal growth factor receptor 2 (HER2, erbB2 or neuB2). 
HER2 is a protein which is involved in cell development. The stage of the breast cancer has 
implications for the choice of treatment.  
Treatment 
Surgery is the main treatment for breast cancer at the earliest stages (Breast Cancer, 2009). 
Earlier the whole breast would be removed during surgery, but now the usual method is 
breast conserving surgery. Also, in the earliest stages sometimes surgery is not enough to 
remove all of the tumour tissue. In such cases supplementary treatment is normal praxis. One 
type of adjuvant therapy is radiation. Especially for patients who have late stage cancer with 
metastases, the lymph node in the armpit is removed through radiation therapy. 
Pharmaceuticals are another type of treatment to cure breast cancer (Nasjonale faglige 
retningslinjer. Nasjonal handlingsprogram med retningslinjer for diagnostikk, behandling 
og oppfølging av pasienter med brystkreft, 2007). One pharmaceutical treatment is adjuvant 
hormonal therapy. This treatment is only given to patients who have cancer tumours that are 
affected by hormones. The reason for this is that tumours which are affected by hormones 
have receptors that the pharmaceuticals attach to. Another pharmaceutical treatment is 
adjuvant non- hormonal therapy, which is also called chemotherapy or cytostatica. There are 
several types of cytostatica, and for breast cancer patients, a combination of different 
cytostaticas is often more effective than the use of only one.  
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Side-effects of treatment 
The treatments for breast cancer are effective, but they all have side-effects. Which treatment 
to choose primarily depends upon the type of breast cancer a patient has, but also on patients 
preferences, because the choice of treatment may imply trade-off between effects and side-
effects. Shared descision-making therefore requires that the patient patient is properly 
informed about effects and side-effects. 
For breast surgery, several post-operative problems could occur like infections, fluid 
leakage from the drain and seromas, which are fluid collection beneath the surgical site 
(Lynn, 1999). Signs of infections are fever, swelling around the drain site or incision. Pain in 
the body is also a normal side-effect from breast surgery. Discomfort in the axilla and pain 
connected to specific exercises recommended after surgery is particulary normal. Depression 
is not an unusual side-effect, because parts or all of the breast is removed during the surgery. 
Side-effects from hormonal therapy are hot flashes, decrease in libido, depression, vaginal 
dryness and irregularity in the menstrual cycle. Other possible side-effects from hormonal 
therapy are eye problems such as cataracts, corneal scarring and retinal changes. For 
premenopausal women, the tamoxifen stimulates the ovaries, which in turn increases 
progesterone and estrogen levels, and this could lead to an increase in the incidence in 
ovarian cysts and stimulate ovulation while blocking the estrogen in the breast. Vaginal 
dryness is also a common side-effect of hormonal therapy. For chemotherapy the fast-
growing cells are affected. Therefore, side-effects attached to this treatment are hair loss and 
low level of white blood cells. Patients who have low levels of white blood cells are more 
susceptible to infection. Another side-effect of the chemoterapy is that patients can 
sometimes feel constant hunger and gain weight while they are on chemotherapy. Other 
important side-effects from chemoterapy are nausea and alterations in taste of food and 
odors.   
1.2.4 Prostate cancer 
Prostate cancer is the most frequent type of cancer in men, and the frequency increases with 
increasing age (Næss, 2002). In 2006, there were 1042 fatal cases caused by prostate cancer 
in Norway (Kreftstatistikk, 2009). In 2006, 3815 men had the diagnosis prostate cancer. In 
2006, no men between 0 to 29 years had the diagnosis, while the number was 577 for men 
30-54 years, 9960 for men 55-74 years and 6932 for men older than 75 years.  
Prostate cancer is slow-growing (Næss, 2002). It arises in the peripheral parts of the 
prostate gland, and starts developing from semen-secreting cells (Prostate cancer, 2009). 
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The primary metastases from a prostate tumour are found in the bone marrow, mostly in the 
pelvis and columna. The growth of the tumour and the metastases is triggered by male 
hormones.  
Staging 
For prostate cancer, as for breast cancer, the most frequently used staging system is the four-
stage TNM system (Tumour Node Metastases) (Prostate cancer, 2009).This system takes 
into account the size of the tumour, the number of lymph nodes involved and the presence of 
distant metastases. In stage level I and II, the cancer is located in the prostate gland only, 
while in stage III and IV, the tumour has spread to other parts of the body (Silva & Abdel-
Wahab, 2008): 
Table 2: Description of the TNM system for prostate cancer 
Stage Description 
Stage I:  
T1a N0, M0, 
G1 
Tumour incidental histologic finding ≤ 5% of resected tissue. 
The histologic grade is “well differentiated”, G1. 
Stage II:  
T1a N0, M0, 
G2/ G3-4               
Tumour incidental histologic finding ≤ 5% of resected tissue.  
The histologic grade is from “moderate differentiated” to “poorly differentiated or 
undifferentiated”, from G2 to G3-4. 
T1b, N0, M0, 
G1 – G3-4 
Tumour incidental histologic finding >5% of resected tissue. The histologic grade is from “well 
differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T1c, N0, M0, 
G1 – G3-4 
Tumour is identified by needle biopsy. The histologic grade is from “well differentiated” to 
“poorly differentiated or undifferentiated”, from G1 to G3-4. 
T1, N0, M0, 
G1 – G3-4 
Clinically inapparent tumour neither palpable nor visible by imaging. The histologic grade is 
from “well differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T2, N0, M0, 
G1 – G3-4 
Tumour is confined within the prostate. The histologic grade is from “well differentiated” to 
“poorly differentiated or undifferentiated”, from G1 to G3-4. 
T2a, N0, M0, 
G1 – G3-4 
Tumour involves one-half of one lobe or less. The histologic grade is from “well differentiated” 
to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T2b, N0, M0, 
G1 – G3-4 
Tumour involves more than one-half of one lobe, but not both lobes. The histologic grade is 
from “well differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T2c, N0, M0, 
G1 – G3-4 
Tumour involves both lobes. The histologic grade is from “well differentiated” to “poorly 
differentiated or undifferentiated”, from G1 to G3-4.  
Stage III: 
T3, N0, M0, 
G1– G3-4 
Tumour extends through the prostate capsule. The histologic grade is from “well differentiated” 
to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T3a, N0, M0, 
G1 – G3-4 
Extracapsular extension (unilateral or bilateral). The histologic grade is from “well 
differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
T3b, N0, M0, 
G1 – G3-4 
Tumour invades seminal vesicle(s). The histologic grade is from “well differentiated” to “poorly 
differentiated or undifferentiated”, from G1 to G3-4. 
Stage IV: T4, 
N0, M0, G1 – 
G3-4 
Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, 
external sphincter, rectum, levator muscles, and/or pelvic wall. The histologic grade is from 
“well differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
Any T, N1, 
M0, G1 – G3-
4 
Tumour is from “incidental histologic finding is equal to, or less than 5% of resected tissue” to 
“fixed or invades adjacent structures other than seminal vesicles: bladder neck, external 
sphincter, rectum, levator muscles, and/or pelvic wall,”- from T1a to T4. Regional lymph nodes 
are “metastasis in regional lymph node(s) – N1. The histologic grade is from “well 
differentiated” to “poorly differentiated or undifferentiated”, from G1 to G3-4. 
Any T Tumour is from “incidental histologic finding is equal to, or less than 5% of resected tissue” to 
“fixed or invades adjacent structures other than seminal vesicles: bladder neck, external 
sphincter, rectum, levator muscles, and/or pelvic wall,”- from T1a to T4. Regional lymph nodes 
is from “no regional lymph node metastasis” to “metastasis in regional node(s) - from N0 to N1. 
Distant metastasis is “distant metastasis” – M1. The histologic grade is from “well 
differentiated” to “poorly differentiated or undifferentiated” - from G1 to G3-4. 
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Staging is an important part of evaluating prostate cancer in order to choose therapy. A 
prostate biopsy reveals if there is cancer in the sample, and at which stage it is. The Gleason 
staging system rates prostate tumours from 2 to 10, where 10 is the most sever type of 
cancer. At this level the tumour has the most abnormalities. For this system the decision of 
the level of the tumour is made in two steps. First, the pathologist examines the tumour 
under a microscope and gives the most common pattern of the tumour a number from 1 to 5. 
Then the pathologist gives the second most common pattern a number, and the sum of these 
two numbers is the Gleason score. A third staging system is the Whitmore-Jewett system. 
Detection 
Different investigation methods can be used to identify the stage of the cancer (Silva & 
Abdel-Wahab, 2008). The different methods are specialised to detect different stages of the 
cancer development. They are computer tomography (CT) and magnetic resonance imaging 
(MRI), bone scanning radioactive isotopes, endorectal coil magnetic resonance imaging and 
prostate biopsy. The computer tomography is used to examine the size of the primary tumour 
and potential spread within the pelvis. The bone scan is used to examine whether the cancer 
has spread to the bones and to reveal possible osteoblastic appearances, which occur because 
of an increased bone density in the areas of bone metastasis. The endorectal coil magnetic 
resonance imaging is used to closely examine the prostatic capsule and the seminal vesicles.  
Treatment 
There are several treatment options for prostate cancer, and the choice of treatment basically 
depends upon two factors: the stage of the tumour and the patient’s preferences for side-
effects of the treatment. Different types of treatments can be used either alone or in 
combination. 
 Because prostate cancer is a disease which develops slowly, watchful observation is 
one option for early prostate cancer (Prostate Cancer, 2009). For patients without 
metastases, there are three active treatments: radical prostatectomy, external beam radiation 
and brachytherapy. Removal of the prostate through surgery, prostatectomy, is the most 
common treatment when the tumour has developed and is at an early stage, or if the cancer 
has failed to respond to radiation therapy. Both radical prostatectomy and laparoscopic 
radical prostatectomy are methods used to remove the prostate. Radiation therapy kills 
prostate cancer cells with ionising radiation, and is a treatment used at all stages of prostate 
cancer. There are two types of radiation therapy, external beam radiation therapy and 
brachytherapy.  
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Chemotherapy is used for metastatic prostate cancer and uses pharmaceuticals. All 
types of chemotherapy acts by killing cells that divide rapidly. This is why chemotherapy is 
used only on late stage prostate cancer tumours, since tumours at an early stage divide 
relatively slowly and are affected by the chemotherapy only to a lesser extent.  
Prostate cancer is stimulated by androgens. To stop androgen stimulation, patients 
may have surgical removal of the testicles (orchiectomy) or pharmaceutical treatment. 
LHRH agonists are one of the most commonly used pharmaceutical therapies (Prostate 
Cancer Info. Hormone therapy, 2009). Such pharmaceuticals block the release of the LHRH, 
which is released before the testosterone is produced. This restrains the growth of the 
tumour.  
Cryotherapy is a treatment which uses cold to treat the prostate cancer. Needles 
which produce cold temperature are inserted into the prostate gland. At freezing temperature 
the needles destroy the whole prostate.  
High Intensity Focused Ultrasound (HIFU) is a treatment which destroys tissue by 
rapid heat elevation (What Is High Intensity Focused Ultrasound (HIFU)?, 2009). 
Ultrasound waves are focused on the cancer tissue, which is rapidly heated up to 90 degrees 
Celsius and then destroyed.  
For all stages of prostate cancer, the passage for urine may be blocked, and this 
blocking has to be opened. This is done by a transurethral resection (TUR).  
Symptoms 
There are usually no symptoms for prostate cancer at an early stage (Prostate cancer, 2009). 
Symptoms for prostate cancer at more advanced levels are frequent urination (especially at 
night), difficulties with starting and maintain a steady stream of urine, painful urination and 
bloody urine. Sexual function problems such as difficulties achieving erection and painful 
ejaculation are also normal. Fatigue and especially pain are frequent symptoms with 
metastases. 
Side-effect of treatment 
Side-effects of the different treatments of prostate cancer are many, and the most common 
ones are impotence, erectile dysfunction and incontinence (Prostate cancer, 2009). For 
surgery the most common complications are impotence and loss of urinary control. Radical 
prostatectomy can give preoperative complication and sexual and urinal dysfunctions. 
External beam radiotherapy and brachytherapy may cause diarrhoea, rectal bleeding, urinary 
incontinence and impotence.  
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The external beam radiotherapy carries the risk of long-term troublesome bowel 
problems, while brachytherapy can give acute urinary symptoms and long-term risk of 
proctitis.  
For therapies which blocks androgen stimulation, side-effects encompass 
psychological problems, weight gain, enlargement of the breasts, hot flashes, osteoporosis, 
impotence and loss of libido. The severe and chronic side-effects of therapies, even with 
curative goals, means that patients involvement in choice of therapy is critical. 
1.3 Tailored Internet support 
Tailored Internet support is one solution to provide patients with reliable and up-to-date 
information about their own disease, which is one of the criteria for shared decision-making. 
The support system can improve a patient’s self-efficacy, which is a person’s level of 
confidence that he or she can perform specific health behaviour (Merluzzi et al., 2001). The 
level of self-efficacy is an indicator for how well a person can improve his functional status. 
WebChoice is a tailored Internet support system developed at the Center for Shared 
Decision Making and Nursing Research at Rikshospitalet University Hospital in Oslo. In 
addition to WebChoice there are other examples of Internet support systems such as CHESS, 
ComputerLink and HeartCare. CHESS is an Internet-based health promotion system. It 
provides information, decision-making support and emotional support services. It was 
developed by a group of scientists at the University of Wisconsin in Madison and was 
initially called the Wisconsin project (Schwitzer, 2002). ComputerLink was especially 
designed for patients with HIV/AIDS (Gustafson et al., 1999). The system provides 
information, communication and self-care guidance services. HeartCare was especially 
designed for patients recovering from Coronary Artery Bypass Surgery (Brennan et al., 
2001). The support system provides information and support services.  
1.4 WebChoice 
WebChoice is a tailored Internet support system and is the intervention to be tested in the 
randomised controlled trial presented in this thesis. The core of WebChoice is an Internet 
site, and username and password are needed for access. It was designed for individually 
tailored illness management for cancer patients and is especially created to assist cancer 
outpatients in their everyday life (WebChoice – internettjeneste for kreftpasienter, 2009 and 
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Ruland, 2006). WebChoice is an extension of a system called CHOICE (= Creating better 
Health Outcomes by Improving Communication about patients’ Expectations). CHOICE is a 
support system for preference-based care planning based on handheld-computers. Today 
CHOICE is available for inpatients at one clinic at Rikshospitalet University Hospital.  
WebChoice provides patient-centred information both at an individual level and a 
general level, and gives the patients an opportunity to communicate with other cancer 
patients and a nurse specialised in cancer care. The patients cannot communicate with a 
physician through WebChoice. The web site WebChoice has three components: an 
assessment component, an information component and a communication component. All 
three components consist of several pages or links to other underlying pages, or other sites 
on the Internet.  
WebChoice’s start page is depicted below (figure 3). It consists of eight links, one of 
them to the Norwegian Cancer Society. Three of the links provide information about 
WebChoice, one link provides advice, one link points to the patient’s personal diary and one 
link guides the patient to one of the three main parts of WebChoice, the link “Min helse” 
(“My own health”- my translation). 
Figure 3: The front page of WebChoice 
 
1.4.1 Assessment component 
The assessment component consists of a patient assessment tool for symptoms and problems 
that are typical for cancer patients. The symptoms and problems are both for functional, 
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physical and psychosocial conditions that could arise for cancer patients. The assessment 
component consists of three parts: one part where patients can register their problems, a 
second part where patients can get advices on how to deal with their specific problems and 
where they can register which solutions they choose for the problems, and a third part where 
the information the patients have registered in the two first parts is summarised in three 
different reports, which all have different aims.  
One report is for the patient only and her or his relatives. The purpose of this report is 
to make it easier for the patient to remember what action were taken to deal with different 
problems. A second report is intended for the physician. The purpose of this report is to 
receive up-to-date information about the patient’s condition and what has been done to ease 
any problems in the last period. A third report is a trend report which shows the development 
of the patient’s health condition during the whole period from the start of the registration. All 
in all this part of WebChoice consists of five main links, and several links from the three 
links.  
1.4.2 Information component 
The information component gives the patient information about the disease and information 
about other Internet resources that are reliable and relevant to the patient’s condition. The 
information component is divided into four parts. One part provides information about the 
patient’s cancer type (in this case either prostate cancer or breast cancer): about the nature of 
the cancer, about the causes of the cancer, about the different examination methods and 
treatments, about the side-effects of the treatments, about the follow-up after treatment, 
about alternative- or complimentary treatments and national statistics of cancer.  
Another part provides information about how to deal with the cancer in everyday life: 
about diet and nutrition, about physical activity, about how to talk about the cancer disease, 
about sexuality, about job-related issues, about when to contact the physician, about 
pharmaceuticals and how to use them, about relapse and spread of cancer, about how to be a 
relative and about fatigue. A third part provides information about patient rights. A fourth 
part gives information about other web sites which have relevant and reliable information 
concerning cancer. All in all, the information component consists of 28 links.  
1.4.3 Communication component 
The communication component consists of two parts. One part is a discussion forum where 
everyone who has access to WebChoice can join. In this forum everybody can ask questions 
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and reply to questions. When needed, a nurse joins the forum and gives advice, or starts a 
discussion which could be of relevance for cancer patients. There are also forums where only 
either breast cancer patients or prostate cancer patients are intended to join, or the discussion 
is not relevant for other cancer patient group. The other part of the communication 
component is a private one-on-one communication with a nurse. 
1.4.4 Experiences with WebChoice 
Patients have actively used all functions of WebChoice and several patients have used the 
program several times per week. A tendency has been that patients, who were recently 
diagnosed, frequently use the information component. Another tendency has been that 
patients who have had the disease for some time frequently use the communication 
component. An analysis of the first six months conducted by the research team has shown 
that patients actively make use of the possibility to personally contact a cancer nurse 
(Ruland, 2007). 
1.5 Health related quality of life 
When evaluating health interventions, there is a need to measure health. But how can health 
be defined and measured? The Constitution of the World Health Organization gave the 
following definition in 1948: “A state of complete physical, mental and social well-being, 
and not merely the absence of disease and infirmity.” The concept of well-being calls for an 
emphasis on a person’s own experience of a health state, which is increasingly recognised in 
professional health care and politics (Brazier et al., 2007). When measuring health, it is in 
other words not enough to just count nights spent in hospitals or to solely rely on the 
physician’s examination. The patient must evaluate his own health.   
The following section will describe how health can be measured and how health-
benefits can be evaluated.  HRQOL is the main endpoint for this randomised controlled trial 
on the effects of WebChoice.  
1.5.1 Economic evaluation 
In a context of limited resources, output must always be measured and compared with input 
to evaluate options. Economic evaluation can be described as “the comparative analysis of 
alternative courses of action in terms of both their costs and consequences”  (Drummond et 
al., 2005, p. 9, italics in original removed). The core aspects are inclusion of both input and 
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output, and a comparison of at least two interventions. When these aspects are included, it is 
possible to make choices that maximise desired outcome within limited resources. 
A partial economic evaluation only evaluates one alternative and/or is only concerned 
with either costs (inputs) or consequences (outputs). Depending on different “combinations”, 
the following types of partial economic evaluation can be identified (Drummond et al. 2005): 
 Outcome description: Examines the consequences of one alternative. 
 Cost description (Cost of illness): Examines costs of one alternative. 
 Cost-outcome description: Examines costs and consequences of one 
alternative. 
 Cost analysis: Examines costs of two or more alternatives 
 Efficacy or effectiveness evaluation: Examines consequences of two or more 
alternatives. 
Consequences can be put in three categories: Natural units, monetary units and utility. This 
gives three different main types of full economic evaluations:  
 Cost-benefit analysis: Costs and effects are measured in monetary units.  
 Cost-effectiveness analysis: Costs are measured in monetary units, and effects 
are measured in natural units.  
 Cost-utility analysis: Costs are measured in monetary units and effects are 
measured in QALYs.  
The cost-utility analysis is by some seen as a subgroup of cost-effectiveness analysis, since 
the two methods are similar in several aspects. The main difference between the two is that 
cost-utility analysis uses a generic measure of the outcome and is therefore in principle 
comparable across all diseases and patient groups, while the cost-effectiveness uses a 
measure of outcome which is specific to the program under study.  
This master thesis is a partial economic evaluation of WebChoice: It can be classified 
as an effectiveness evaluation, since it only measures consequences of two alternatives. The 
consequences are measured in utility (HRQOL and quality adjusted life years - QALYs), so 
the study can be part of a later cost-utility analysis.   
1.5.2 Preferences 
Preference is an umbrella term which covers values and utilities (Drummond et al. 2005): 
Values are preferences under certainty, while utilities are preferences under uncertainty. 
Certainty concerning future health outcome can only be found at a theoretical level, which 
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means that all preferences concerning health are in general referred to as utilities in health 
care terminology.  
The concept of utility in a strict economic sense was first developed in 1944, by John von 
Neumann and Oscar Morgenstern, a mathematician and an economist respectively 
(Drummond et al., 2005). Through their theory of rational decision-making under 
uncertainty, they constructed the concept of utility. This theory is today known as utility 
theory or von Neumann-Morgenstern utility theory. They developed a normative model 
where they described how rational individuals “ought” to make decisions when faced with 
uncertain outcomes. For this purpose they defined what they meant by rational behaviour 
under uncertainty. This was expressed through different axioms which defined preferred 
options under different scenarios of uncertainty. These axioms provide the foundation for 
modern decision theory and for specific preference measurements in health care.  
Measuring health preferences 
There are several methods to measure preferences for health states. The three most widely 
used techniques are the category rating/ scaling, the standard gamble (SG) and the time 
trade-off (TTO) (Drummond et al., 2005).  
When using category rating, the patient ranks different health outcomes. The scale 
may include numbers, and the numbers may be presented in categories (category scaling). In 
a visual analogue scale (VAS), the scale just consists of a line. The different scaling 
techniques can be combined.  
The standard gamble is the classical method for measuring cardinal preferences, and 
it is based directly on the fundamental axioms of the utility theory of von Neumann and 
Morgenstern. The respondent is offered two alternatives, where the first alternative is 
treatment with two outcomes: perfect health or death, and the second alternative is no 
treatment with a certain health status lower than perfect health, for the rest of the patient’s 
life. The outcomes in the treatment-alternative have to include their probability, and the 
introduction of risk makes this method a measurement of utility in economic terms. 
The time trade-off was developed specifically for use in health care. The time trade-
off is a method for measuring preferences were the patient has to choose between two 
alternatives: a) Stay in a specific health state for a specific time period t followed by death, 
or b) Have perfect health for a time period x, which is less than the time period t. Then the 
time period x is varied until the patient values the alternatives as equal.  
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Multi-attribute health status classification systems with preferences scores  
The use of the rating scales, the time trade-off and the standard gamble is time consuming 
and complex. For instance, the standard gamble and TTO often requires face-to-face 
interviews to ensure that the respondent fully understand the concept of probability 
(Drummond et al., 2005). In this context, faster and more simplistic methods have been 
introduced to measure preferences in large-scale surveys.  
Pre-scored multi-attribute health status classification systems are tools to measure 
preferences for health outcomes or HRQOL and are meant for surveys with a large number 
of respondents. The requirements for a useful generic classification system are: Feasibility 
and general applicability, reliability, validity and sensitivity.  
The most frequently used systems are the Quality of Well-Being, Health Utilities 
Index, EQ-5D and Short Form 6D. Other systems are 15D and Assessment of Quality of Life 
(Drummond et al., 2005).  
All classification systems consist of a descriptive system in a questionnaire and a 
summary index. The questionnaire has different numbers of questions or dimensions, 
according to different types of systems. System-names often indicate the number of 
dimensions, like five dimensions in the EQ-5D and fifteen in the 15D. 
Each dimension has a set of predetermined levels, and the number of levels differs 
across the systems. The levels are classified with an ordinal number: 1 is the best health state 
for the dimension and the highest number is the worst.  
The summary index is an index where 0 represents death and 1.0 represents perfect 
HRQOL. Some multi attribute systems have index values below 0 (e.g. EQ-5D). The 
summary index is created on the basis of the respondent’s scoring on the dimensions, using 
an algorithm to incorporate preferences. The basis of the algorithm is typically TTO or VAS 
values from interviews of representative samples of the general population. The results from 
complex and time consuming preference surveys are hence incorporated in pre-scored multi-
attribute systems, which make them adequate for large scale surveys. 
1.5.3 The 15 D 
The 15D is a multi-attribute health status classification system (Brazier et al., 2007). It is 
generic, multi-dimensional, standardised and self-administrated (Sintonen, 1994). The 15D 
was designed to meet the requirement for a useful generic measure as far as possible.  
The 15D consists of two parts. The first part is the health state descriptive system, 
which is formed as a questionnaire. It consists of fifteen questions with five alternative 
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response categories for each question. The dimensions cover most of the content in any 
preference-based measure (Brazier et al., 2007). For each question, response category 1 
indicates no problems with the dimension in question, and 5 indicates severe problems. In 
the questionnaire, the respondent tick off only the answer to each question which best 








 Usual activities 
 Mental function 
 Discomfort and symptoms 
 Depression, distress 
 Vitality 
 Sexual activity 
The second part of the 15D is a valuation system which is based on a simple, additive 
algorithm. The system puts a health state value on each of the five dimensions for each of the 
fifteen questions. The method used to calculate the values is a variant of VAS. 15D has been 
evaluated in five population based samples in Finland and one in Denmark. 
1.5.4 Quality-adjusted life years (QALYs) 
In a cost-utility analysis the measure of benefit is QALYs, which is based on HRQOL and 
the length of time of the health benefit (Drummond et al., 2005). When measuring HRQOL 
in the context of health economics, the idea is that the respondents express the preference for 
different health states. This is typically done with a method that forces the respondent to 
make a trade-off between HRQOL and another good (e.g. length of life or money). This 
means that HRQOL, and consequently QALYs, express preferences for health 
improvements.  
The concept of QALYs was introduced by Herbert Klarman and his colleagues in 
1968 (Drummond et al., 2005). The QALY captures time and a person’s health state, and it 
is based on the relative desirability of different outcomes. The QALY consists of a 
combination of two dimensions: time and health state, or quantity and quality. This indicates 
that the QALY simultaneously captures health gains from reduced morbidity and reduced 
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mortality. For an individual, his/her total QALYs will be given by the sum of quality-
adjusted time periods (Manca et al., 2005). This can be expressed as:  
QALYs = 
nΣj=1= Qj * tj  
Q is the 15D index score, t is time, j is the interval number, n is the number of subintervals. 
Depicted in a figure, the QALYs gained is the area between the expected life curve without 
the intervention and the expected life curve with the intervention. 
Figure 4: A person’s QALYs with and without the intervention 
Perfect 
health 1.0  
Dead 0.0    
Intervention  Death 1  Death 2   
Dark grey = with intervention. Light grey = without intervention 
The expected QALY for a person is calculated as the sum of each pathway weighted by its 
respective probability. This is called the area under the curve (AUC) method.  
To measure change in QALYs in randomised clinical trials, three different methods 
may be used: Linear change, earlier level maintained and change at midpoint. Of the three, 
the linear change is most used in such contexts (Manca et al., 2005).  
1.5.5 How to achieve the highest possible HRQOL 
Patients with breast cancer or prostate cancer at an early stage do usually not have severe 
symptoms, but the treatments may give severe side-effects (see section 1.2.3 and 1.2.4). It is 
therefore a trade-off between treatment effectiveness and side-effects, which in many cases 
is equivalent to a trade-off between to live longer with more pain versus to live shorter with 
less pain (Brazier et al., 2007). In such cases, shared decision-making is especially important 
because it is the patient himself who knows best what his preferences are, and the patient 
cannot make such trade-offs unless they are properly informed. When the patient participates 
in the decision-making process, this will likely lead to better outcomes for the patient and 
hence the highest possible HRQOL score for the patient.  
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1.6 Epidemiology and study design 
Epidemiology is the science and practice of detecting and explaining disease patterns in 
populations (Bhopal, 2002 and Thelle, 2004). The objective is to prevent and control disease, 
and to improve health by analysing effects of different medical or non-medical interventions. 
When measuring these aspects, the two core measures are prevalence and incidence. 
Prevalence is defined as the number of persons who, at a specific point in time, have a given 
disease. While prevalence measures the distribution of a disease, incidence incorporates a 
time factor and is a measurement for development: Incidence is defined as the number of 
new cases of a disease during a specified period of time.  
Within epidemiology there are different types of study design which fit different 
types of research situations. The four main types of epidemiologic study designs are cross-
sectional study, case-control study, cohort study and trials (Thelle, 2004). It possible to add 
case series in this line up, but since case series typically are used as background for the other 
studies, it will not be discussed here (Bhopal, 2002). The following description of designs is 
largely based on Thelle (2004) and Bhopal (2002). 
A cross-sectional design studies health and disease states in one or more populations 
at a defined time and place. As the name indicates, this type of study is a “slice” of time and 
place which explores prevalence of a disease or other exposures. Cross-sectional studies can 
test hypotheses by identifying correlating results. The study can be repeated to measure 
change. This is called repeated cross-sectional design or panel design. The problem with a 
cross-sectional design is difficulties in detecting causality and development, since there is no 
randomisation and the respondents will in principle be new in each new study. 
A case-control design compares a group with a specific disease (case group) to a 
similar group without the disease (control group). The researcher identifies differences and 
similarities between the two groups, for instance that lung cancer patients smoke more 
tobacco than persons without lung cancer. These types of studies typically involve collecting 
extensive medical and social background data for the respondents.  
A cohort design follows a specific group of people over a time period. The group, or 
cohort, is defined by common characteristics, for instance that all of the members have a 
given disease or take part in a specific lifestyle. The measure of interest is often incidence, 
where the study seeks to measure the number of new cases. The cohort can be compared to a 
control cohort. It is possible to link exposure (e.g. alcohol use, use of drugs) to outcomes 
(e.g. liver problems) in cohort studies.  
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The participants in a trial are divided into two (or more) groups, where one group is 
exposed to an intervention and the other is not. A trial design has many similarities with a 
cohort design, but with one important difference: The exposure is deliberately changed and 
controlled. When the intervention group has been selected on the basis of randomisation, the 
design is called randomised controlled trial (RCT). The randomisation process prevents 
confounding, since the groups, in principle, are equal in all respects except for the exposure. 
Any difference in outcome can then be attributed to the exposure, and hence such trials are 
typically used to test hypotheses of causality. In epidemiology, randomised controlled trials 
can be used to analyse treatments, but is rarely used to investigate exposures with presumed 
negative health effects, due to ethical issues.      
A problem in all study designs is the risk of bias. Bias can be defined as systematic 
errors, both intentional and unintentional, that favour certain outcomes (Bhopal, 2002 and 
Thelle, 2004). Confounding is a major cause of bias, and may lead to a wrong conclusion 
about the relationship between exposure and outcome. A high level of exposure (e.g. non-fat 
milk) may correlate with outcome (e.g. overweight and obesity), but the cause may be a 
hidden, third factor (historical example in Thelle (2004): non-fat milk did not cause obesity, 
but obese persons had the highest consumption of non-fat milk because they were on a diet). 
Two other main biases are information bias and selection bias. A selection bias is a 
systematic difference between the intervention and control group in terms of more than the 
exposure. This bias derives from the method of data collecting, for instance that the 
recruitment process was flawed. Information bias is one or more errors in interpretation, 
collection and/or analysis of data. This type of bias ranges from false assumptions in the 
hypotheses (e.g gender affects intelligence), or manipulation of the results by the 
respondents, both deliberate and unintentional. 
1.7 Research questions and hypotheses 
Cancer is likely to impact HRQOL negatively (Juver & Vercosa, 2008). However, 
information and advice from WebChoice may relieve several of the problems patients 
encounter and may consequently reduce the negative impact of the disease.  
When capturing health related quality of life with the 15D instrument, I would, on the 
basis of the previous presentation (see section 1.2 - 1.5), expect that WebChoice may 
improve HRQOL along 8 of the 15 dimensions of 15D: 
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 The patients in the intervention group have less problems with their sleep because 
they receive advice about how to avoid sleeping disorders.  
 The patients in the intervention group have less problems with eating because they 
learn about which effects different cancer treatments can have on their appetite, and 
how some cancer treatments can change the taste of food.  
 The patients in the intervention group have less problems with their bladder function 
and bowel function because they get advice on how to ease problems with these 
functions.  
 The patients in the intervention group have less symptoms and less problems with 
their mental function because they learn how to deal with symptoms and because 
they can discuss problems with other patients who have experienced the same 
problems as themselves, and with nurses. 
 The patients in the intervention group experience less depressions because they 
discuss problems concerning the cancer disease with other patients and with nurses.  
 The patients in the intervention group are less distressed because they have more 
knowledge about the disease and side-effects of different treatments and because they 
know that if they are worried about something, they can ask a nurse about it and be 
sure that they will get an answer the same day.  
 The patients in the intervention group are healthier and more energetic, because they 
can ask for help about the best way to deal with an illness and what the best nutrition 
is for a cancer patient who gets a specific treatment and suffers from specific side-
effects. 
 The patients in the intervention group have less problems with their sexual functions 
because they receive much information about how the disease impacts the sexual 
function.  
WebChoice may also provide information which makes the patients more competent to 
participate in shared decision-making, hence assure them treatment according to their 
preferences. This, in turn, may improve the patients’ HRQOL, as it is sensitive to patient 
preferences.  
The main hypothesis is therefore that patients using WebChoice score better on 8 out 
of 15 HRQOL dimensions and hence have a better 15D summary score (index) after one 
year of intervention, compared to “usual care” (the control group).  
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2. Methods 
The design, patient recruitment and execution of the trial were performed by the research 
team. During the rest of this methods section, I will describe how the study was designed 
and implemented by the research team, and how data were subsequently analysed by myself.  
2.1 The WebChoice randomised clinical trial 
The Centre for Shared Decision Making and Nursing Research at Rikshospitalet University 
Hospital in Norway carried out a randomised controlled trial of WebChoice during 2007 and 
2008. The head of the research centre and the principal investigator was Professor Cornelia 
M. Ruland, and Laura Slaughter was the co-investigator.  
The participants in the trial were prostate cancer patients and breast cancer patients 
from all parts of Norway. They were recruited through advertisement on the Internet, in 
national newspapers, in weekly magazines, on national television programmes and through 
flyers handed out in outpatient clinics across the country. The recruited patients were 
randomised into two different groups, the intervention group, or WebChoice group, and the 
control group.  
During the trial period, the intervention group had access to the website WebChoice 
in addition to normal care, while the control group received only normal care (see section 
1.2). The trial period was one year. Five times during this period (at baseline, after three 
months, after six months, after nine months and after twelve months) both groups received a 
data collection package from the research team. Both groups received the same package for 
each period, but the content was not identical at every dispatch.  
All of the packages included a information letter and a registration form for 
symptoms and pain called the memorial symptom assessment scale (MSAS). Most packages 
also contained one of the following registration forms where the patients could register their 
choice of actions taken to handle the disease: The Cancer Behaviour Inventory (CBI), the 
social support (MOS), a form for registration of depression (CES-D) and the diary.  
In three of the five packages, the form Patient Preferences in participating in 
Decision Making (Degner) and the HRQOL questionnaire 15D were included. The following 
elements were included in only one package: the informed consent form, the Buypass form 
which was the registration form for access to WebChoice, a demographics form, a 
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questionnaire about ease of use of WebChoice, and a form for health related information use 
and usage, which was different for the WebChoice group and the control group.  
2.1.1 Inclusion criteria and exclusion criteria 
There were several criteria for inclusion of the participants in the randomised control trial, 
and one exclusion criterion. 
Inclusion criteria: 
 Written informed consent 
 Age 18 or over 
 Mentally healthy 
 Able to talk and write Norwegian 
 Access to Internet and a computer with Microsoft Windows operating system 
(version 98 or later) 
 For breast cancer patients: Had received or planned to receive surgery, and received 
or planned to receive one adjuvant therapy, except for radiation therapy only 
 For prostate cancer patients: Had received or received treatment for the disease 
Exclusion criterion: 
 Metastases of the brain, treated with radiation therapy 
2.1.2 Recruitment  
Interested persons were invited to contact the research team for participation in the 
randomised controlled trial. Relatively few people showed interest in joining the randomised 
controlled trial, and the research team made several attempts to recruit participants over a 
time period of more than a year. The start of the recruitment period was in May 2006 when 
an advertisement was put in the national Norwegian newspaper VG. In June, an attempt to 
recruit patients was carried out by an advertisement in the weekly magazine Se og Hør. Also, 
an article in the regional newspaper Aftenposten about a patient from the pilot study was 
used to recruit patients. The same patient was presented in a morning program on the 
Norwegian national television channel TV 2.  
In July 2006, both written and spoken information about the randomised controlled 
trial was given to clinics that treat breast cancer and prostate cancer patients. In September, a 
description of the randomised controlled trial and a request for people to participate, were 
given in a member magazine for Prostatakreftforeningen (The Prostate Cancer Society – my 
translation), and at the WebChoice webpage. In November, a description of the randomised 
controlled trial and a request for participants was made in the member magazine for 
Foreningen for brystkreftopererte (Society of Breast Cancer Post Operatives – my 
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translation), along with advertisements in the two national papers Dagbladet and VG. In 
February 2007, attempts at recruitment were made by advertising at Sammen mot Kreft’s 
webpage (United Against Cancer – my translation) and in their periodical. 
Prostatakreftforeningen, Foreningen for brystkreftopererte and Sammen mot Kreft are all 
subdivisions of the Norwegian Cancer Society.  
The Cancer Registry of Norway provided national patient lists which were used in 
direct recruitment through letters from the research team. In May 2007, final advertisements 
were made in the two national papers VG and Dagbladet.  
The last patient was recruited on the 15
th
 of June 2007. At this time the number of 
patients included was well below the estimated need, but the recruitment process was 
finished for practical reasons. 
2.1.3 Registration 
Individuals who showed interest in the WebChoice project, but did not participate, were not 
registered. Apparently, a great number of patients contacted the research team, but relatively 
few participated because of lack of interest or because they did not have breast or prostate 
cancer. 
2.1.4 The inclusion process 
In total, 445 breast and prostate cancer patients who contacted the research team met the 
inclusion criteria and were interested in participation. These persons received the “baseline” 
package which included:  
 Information letter 
 Informed consent form 
 BuyPass form  
 Registration form about socio-demographic variables 
 Memorial Symptom Assessment Scale 
 Patient Preferences in Participating in Decision-Making  
 Cancer Behavior Inventory 
 15D Quality of Life questionnaire 
 Social support (MOS) 
 Depression (CES-D) 
 The use of health care diary 
In total, 325 patients returned this first package. Nine of the respondents informed that they 
did not want to participate after all. After three months, 316 persons received the next 
package, and 265 returned it. At this point, 8 of the 316 persons had informed that they did 
not want to participate in the study anymore. After 6 months, 308 persons received the 
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package and 257 returned it. At this point an additional 26 participants among the 308 
withdrew from the study. The fourth package was sent after 9 months to 282 persons and 
242 returned it. At this point seven more patients withdrew. The last package was sent after 
12 months to 275 persons and 245 returned it. Among the 325 who returned the initial 
package, a total of 80 persons did not complete the study.  
Among the 245 patients who participated till the end, 9 did not fill in the 15D 
questionnaire sent after 6 months (but they filled in at baseline and after twelve months). 
This leaves 236 patients for analysis. Of the 236 patients, two patients had more than four 
missing values in the last questionnaire, which made it difficult to include them in analyses 
of the 15D.  
In total, 325 patients returned the 15D questionnaires, once, twice or three times, but 
the subsequent analyses are based on information from the 234 patients who filled in the all 
three 15D questionnaires completely or almost completely. The reason for participants to 
drop out of the study is not known, because a premise for the patients to join the study was 
that they could withdraw from the study at any time without explanation.  
2.1.5 Randomisation  
The inclusion process ended with 325 patients. These patients were randomised into the two 
groups, the WebChoice group and the control group. The randomisation method used was 
the minimisation method to balance covariates (Zeller et al., 1997). The randomisation 
system R-Tool was used for this purpose.  
2.1.6 Endpoints and power 
The primary endpoint of the WebChoice study was symptom distress measured by MSAS. 
Secondary endpoints were self-efficacy, decision-making skills, social support, depression, 
15D and resource use. 
Using symptom distress as the endpoint for power calculation, the research team 
made the assumption based on previous work, that the difference would be 0.3 between the 
WebChoice and the control group. The statistical power was set at 0.80, and the significance 
level at 0.05. The study would then require 140 patients in each group. To allow for 
subgroup analyses, the group sizes were increased to 200. Additionally, the attrition rate was 
expected to be 50 percent, and the research team aimed to recruit 500 patients in each group. 
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The study was approved by the Norwegian Data Inspectorate and by REK, the Regional 
Ethics Committee. 
2.1.8 Literature search  
A literature search was carried out by the research team prior to the start of the study period. 
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2.2 Statistical methods 
2.2.1 Exclusion and inclusion of variables 
I received the data as four SPSS files from the research team (three data sets for the 15D 
scores and one set for demographics). The patients/respondents had answered a large amount 
of questions concerning health, age, income, education, family and so on (see Appendix). I 
had to exclude certain variables in my analysis, due to time limitations. The following 
considerations were made: 
Socio-economic variables and skills 
This study measures the effect of web-based advice and information, so information about 
the patients pre-existing knowledge, skills and ability to acquire and deal with complex 
information is vital. Such data are best acquired through interview tests, but such tests were 
not conducted by the research team. Socio-economic variables can indicate levels of skills 
and are relevant in this study. These types of variables are also important in order to evaluate 
how representative the sample is. I therefore included education, household income and age 
as background variables.  
I did not include the number of children. This variable could have been interesting, 
since teenagers and adult children can provide help and assistance with a tool like 
WebChoice. However, this variable does not provide information on the children’s age or 
skills, so I excluded this variable. 
I also excluded marital status. It could not be used to control household income, since 
it is impossible to specify the income of the spouse. And as with the children variable, it 
does not indicate skills in an “assistance” perspective.  
The patients had answered a question about their experience with computers, but I 
excluded this variable because I found WebChoice so accessible and user-friendly that 
computer experience should have little relevance. The self-evaluation of own experience is 
also not very reliable, as the respondents classify themselves relative to what they consider 
to be “normal”. The exclusion of this variable might have been a mistake in a post-
perspective, as it could have helped to explain the results. 
Time since the cancer diagnosis is an important background variable. It indicates the 
patient’s experience and hence knowledge about own disease. The data set contained the 
date of diagnosis for each patient. The time since diagnosis varied considerably among the 
patients, so I calculated the number of months since diagnosis and divided these into four 
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intervals: 0 - 6 months, 7 - 12 months, 13 - 18 months and 19+ months. The latter interval 
was the reference level when the variable was expressed in terms of three dummies in the 
regression analysis. The precision level of four categories was unnecessary except for the 
regression analysis, so a variable for “new” and “old” cancer diagnoses was constructed. 
New diagnosis was from 0 to 6 months before the start of the survey, and old diagnosis was 
from 7 months or more.  
Health variables 
The patients had answered questions concerning each of the 15D variables. All of these were 
included since these variables are what measure the effect(s) of the intervention. The 15D 
variables at baseline serve as background variables. Eight of the 15D variables were 
analysed separately to address the eight research questions concerning sleeping, eating, 
elimination, mental function, discomfort and symptoms, distress, vitality and sexual activity. 
Additional analysis on the remaining seven 15D-variables are presented in the Appendix. 
Detailed variables describing the patients’ cancer and treatments were excluded. The 
inclusion criteria had to some extend defined the patients’ cancer and treatments, and I found 
the 15D variables more relevant to describe their health. 
I calculated the QALY variable, based on the method of linear interpolation and the 
regression based adjustment described by Manca et al. (2005). The method I used adjusts for 
possible difference in baseline utility. 
2.2.2 Statistics  
Differences between the groups were tested by the chi-square test for categorical variables. 
The variables age and mean QALY were tested by the t-test for independent samples. All 
these tests are two-sided, with a significance level set to 5 percent. Linear regression and 
regression based adjustment were used to estimate the difference in one year QALY between 
the WebChoice and the control group (Manca et al., 2005).  I used the statistical tool SPSS 
for the statistical tests. 
2.2.3 Calculations 
Three main types of calculations were done: Replacing missing 15D values through 
imputation based on linear regression, transforming 15D variables into a summary score and 
finally calculating the number of QALYs for each patient during the study period through 
linear interpolation. The patients were somewhat unbalanced at baseline with respect to the 
15D score, so when I calculated QALYs, I used multiple linear regression to adjust the 
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differences (Manca, 2005). The formula is based on Manca, but was expanded due to more 
groups of interest: QALYi = β0+ β1* ti + β2* ki + β3 * Qi
b
 
i is the ID of the respondent. ti is the treatment arm dummy variable, where 1 is 
WebChoice and 0 is the control group. ki is a cancer group dummy variable, where 1 is 
prostate cancer and 0 is breast cancer. Qi
b 
is the patient specific 15D score at baseline. 
Through a multiple linear regression where 15D score at 12 months were the dependent 
variable, and intervention group, type of cancer and the patient’s specific 15D score at 
baseline were the independent variable, I found the values for  β1, β2 and β3. Then I 
constructed the new variable QALYs.   
To be able to calculate the 15D indexes for the patients, the missing values had to be 
replaced before they were translated into 15D scores. The first operation was carried out by 
the means of two methods explained at the homepage of the 15D (Replacing missing data, 
2009). The main method uses linear regression to replace the missing values. In some cases 
the missing data had to be replaced by the use of the optional method: I removed the 
independent variables which also have missing data for the specific ID, and then I had to run 
the regression once more. This replaced the rest of the missing data in the 15D 
questionnaires, and all the 234 15D indexes were calculated. To translate the 15D values into 
15D score, I used a syntax file available at the 15D homepage.  
2.2.4 Procedure 
The following table is a short description of the procedures during the statistical analyses 
Prior to analyses - Remove empty IDs in all sets 
Demographics - Select/exclude variables 
- Separate analyses according to cancer type 
- Analyses on dropout 
- t-tests on age 
- Chi-square tests on income and education (crosstabs) 
- Construct new variables for time since diagnosis 
- Separate analyses of time since diagnosis 
- Chi-square tests (crosstabs) on time since diagnosis 
Quality of life - Separate analyses on each of the eight variables according to cancer types 
- Chi-square tests (crosstabs)  
15D index - Create new data files with demographics, cancer types, intervention/control and 
all 15D variables for each of the three measurement points.    
- Replace missing values  
- Transform variable values into 15D scores  
- t-tests 
- Manual input of constructed time variables 
- Separate analyses on mean scores according to groups and time since 
diagnosis 
- Linear regression analyses on variables’ impact 
QALYs - Linear interpolation and regression-based adjustment to calculate QALYs 
- Regression analyses on different variables’ impact 
- t-tests of difference in mean QALYs 
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3. Results 
This chapter presents the results of the analyses of this thesis. In total 325 patients were 
included in the randomised controlled trial. Of the 325 patients, 234 filled in the 15D 
questionnaire all three times. The analyses presented in the results section are mainly based 
on the 234 patients who answered all three times.  
3.1 Descriptives 
The characteristics of the 325 patients are given in the table below (table 3). 
Table 3: Characteristics of all patients (n = 325) who accepted to participate and were randomised to 
type of intervention, according to type of cancer and intervention type 
 Breast cancer (n = 189) Prostate cancer (n = 136) 
 WebChoice Control WebChoice Control 
Mean age (SD) 50.6 (7.5) 50.3 (9.4) 66.1 (7.5) 64.9 (8.3) 
Median age 50.0 50.0 66.5 63.5 
Age range 32 (35 – 67) 45 (32 – 77) 33 (47 – 80) 38 (45 – 83) 
Level of education: 
Secondary school or less 
High school 
University/college 4 years or less 





















Level of income: 
Less than 200 000 NOK 
200 000 – 400 000 NOK 
400 000 – 600 000 NOK 
600 000 – 800 000 NOK 

























Within each type of cancer, the randomisation of the 325 patients included in the trial was 
relatively successful in that the groups were relatively well balanced with respect to age, 
education and income within each of the disease groups (table 3).  
The characteristics of the 234 patients who are included in the 15D analyses are 
given in the table below (table 4).  
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Table 4: Characteristics of the patients (n = 234) who responded to the 15D questionnaire all three times 
according to type of cancer and type of intervention 
 Breast cancer (n = 130) 
 
) 
Prostate cancer (n = 104) 
 WebChoice Control WebChoice Control 
Mean age (SD)  52.2 (7.4) 50.9 (9.6)  65.6 (7.1) 66.37 (7.5) 
Median age 51.0 50.0 66.0 65.0 
Age range 31 (36-67)  45 (32-77) 30 (50-80) 27 (55-82)  
Level of education: 
Secondary school or less 
High school 
University/college 4 years or less 






















Level of income: 
Less than 200 000 NOK 
200 000 – 400 000 NOK 
400 000 – 600 000 NOK 
600 000 – 800 000 NOK 

























Within each type of cancer, the randomisation was relatively successful in that the groups 
were relatively well balanced with respect to age, education and income within each of the 
disease groups.  
To test for selection bias, I compared characteristics of the 91 participants who filled 
in the 15D form less than three times with the 234 participants who filled in the 15D form 
three times. Table 5A shows the difference for the breast cancer patients and table 5B shows 
the difference for the prostate cancer patients.  
Table 5A: Characteristics of breast cancer patients (n = 189) who responded to the 15D questionnaire all 
three times (n = 130), and those who responded less than three times (n = 59), according to intervention 
type, WebChoice (n = 96) and control group (n = 93) 
 WebChoice (n=96) Control (n=93) 









Mean age(SD) 52.2 (7.4) 48.4 (7.2) 0.012 50.9 (9.6) 48.2 (8.4) 0.281 
Median age 51.0 48.0  50.0 48.0  
Age range 31 (36-67) 29 (35-64)  45 (32-77) 31 (32-63)  





years or less 
4.University/college 





































Level of income 
(NOK): 
Less than 200 000  
200 000 – 400 000  
400 000 – 600 000  
600 000 – 800 000  








































In the breast cancer WebChoice group, the non-respondents were significantly younger than 
the respondents. This was only a tendency in the control group. When it comes to income, 
the tendencies were somewhat unclear. In both groups, the non-respondents were less 
represented with medium/high income patients, but on the other hand, more of them had 
high income. Educational level was equally distributed between respondents and non-
respondents in the WebChoice group. This was not the case in the control group, where the 
non-respondents tended to be more educated. The WebChoice group had a higher dropout 
rate than the control group (43 percent versus 19 percent).  
Table 5B: Characteristics of prostate cancer patients (n=136) who responded to the 15D questionnaire 
all three times (n=104), and those who responded less than three times (n =32), according to 
intervention type, WebChoice (n=67) and control group (n=69) 
 WebChoice (n=66) Control (n=70) 









Mean age(SD)  65.6 (7.1) 67.65 (8.7) 0.341  66. 6(7.4)  59.1 (9.1) 0.002 
Median age 66.0 68.0  65.0 57.5  
Age range  30 (50- 80) 32 (47- 79)  27 (55- 82) 38 (45 - 83)  





years or less 
4.University/college 












































Level of income 
(NOK): 
Less than 200 000  
200 000 – 400 000  
400 000 – 600 000  
600 000 – 800 000  











































In the prostate cancer group, the non-respondents in the WebChoice group tended to be 
older, have less education and lower household income than the respondents. In the control 
group, the non-respondents were statistically significantly younger, and they tend to have 
more education and higher household income. The latter difference was close to statistically 
significant. There were only small differences in dropout between the WebChoice group and 
the control group.  
Time since diagnosis 
The results of a comparison for the variable time since diagnosis between the WebChoice 
group and control group according to cancer group within the 234 patients who answered all 
three times, are presented in the table below (table 6). 
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Table 6: The distribution of time since diagnosis at inclusion to the trial, according to cancer type and 
type of intervention.  
 Breast cancer (n =130) Prostate cancer (n = 104) 
 WebChoice (n=55) Control (n=75) WebChoice (n=49) Control (n=55) 
0-6 months 9.1% 6.8% 10.9% 5.7% 
7-12 months 7.3% 13.5% 13.0% 24.5% 
13-18 monts 32.7% 43.2% 21.7% 18.9% 
19 + months 50.9% 36.5% 54.3% 50.9% 
p-value 0.285 0.445 
For both disease groups the tendency was that the WebChoice group had a few more patients 
with more recent diagnosis, but the difference was not statistically significant.  
The result of a comparison for a second variable of time since diagnosis between the 
WebChoice and control group according to type of cancer is given in the table below 
(table7).  
Table 7: The distribution of time since diagnosis at inclusion into the trial, according to cancer type and 
type of intervention.  
 Breast cancer (n=130) Prostate cancer (n=104) 
 WebChoice (n=55) Control (n=75) WebChoice (n=49) Control (n=55) 
New: 0-6 months 9.1% 6.8% 10.9% 5.7% 
Old: 7+ months 90.9% 93.2% 89.1% 94.3% 
p-value 0.624 0.343 
Within both disease groups, a tendency was that the WebChoice group had a higher 
percentage of patients with the recent diagnosis. There were no statistically significant 
differences between the WebChoice group and control group. 
3.2 Health related quality of life 
3.2.1 Analyses of the eight relevant 15D dimensions.  
The results for the eight relevant 15D dimensions will be presented in the tables below. The 
first tables (A tables) will present the distribution of the responses to the eight questions for 
all cancer patients in the WebChoice and the control group. In the next two tables (B tables 
and C tables) the 15D scores are presented for each of the cancer types. Number of “stars” 
(*) marks missing values: *) One missing value, **) Two missing values, ***) Three or 
more missing values.  
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Table 8A: 15D scores for the fifth dimension (sleep) for all patients (n=234). 
Sleeping 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months* Baseline 6 months* 12 months 
Valid responses 104 104 103 130 129 130 
1.Sleeping normally 28.8% 24.0% 30.1% 25.4% 30.2% 33.8% 
2.Slight problems sleeping 45.2% 46.2% 39.8% 51.5% 39.5% 38.5% 
3.Moderate problems sleeping 13.5% 21.2% 20.4% 15.4% 20.9% 18.5% 
4.Great problems sleeping 12.5% 8.7% 9.7% 7.7% 8.5% 9.2% 
5.Suffer severe sleeplessness 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 
Chi-square test (p) 0.524 0.698 0.940    
Table 8B: 15D scores for the fifth dimension (sleep) for breast cancer patients (n=130). 
Sleeping 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months* Baseline 6 months 12 months 
Valid responses 55 55 54 75 75 75 
1.Sleeping normally 23.6% 23.6% 27.8% 25.3% 28.0% 32.0% 
2.Slight problems sleeping 45.5% 43.6% 38.9% 49.3% 40.0% 40.0% 
3.Moderate problems sleeping 16.4% 21.8% 20.4% 14.7% 20.0% 17.3% 
4.Great problems sleeping 14.5% 10.9% 13.0% 10.7% 10.7% 10.7% 
5.Suffer severe sleeplessness 0.0% 0.0% 0.0% 0.0% 1.3% 0.0% 
Chi-square test (p) 0.900 0.891 0.920    
Table 8C:15D scores for the fifth dimension (sleep) for prostate cancer patients (n=104) 
Sleep 
 WebChoice (n=49) Control (n=55) 
 Baseline 6 months 12 months Baseline 6 months* 12 months 
Valid responses 49 49 49 55 54 55 
1.Sleep normally 34.7% 24.5% 32.7% 25.5% 33.3% 36.4% 
2.Slight problems sleeping 44.9% 49.0% 40.8% 54.5% 38.9% 36.4% 
3.Moderate problems sleeping 10.2% 20.4% 20.4% 16.4% 22.2% 20.0% 
4.Great problems sleeping 10.2% 6.1% 6.1% 3.6% 5.6% 7.3% 
5.Suffer severe sleeplessness 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.306 0.719 0.962    
For the dimension sleep, there was little difference between the WebChoice groups and the 
control groups (Tables 8A to C), and the differences were not statistically significant. 
Table 9A: 15D scores for the sixth dimension (eat) for all patients (n=234). 
Eating 
 WebChoice (n=104) Control (n=130) 
 Baseline* 6months** 12 months** Baseline 6 months 12months 
Valid responses 103 102 102 130 130 130 
1. Eat normally 99.0% 98.1% 98.0% 100.0% 100.0% 100.0% 
2. Eat with minor difficulty 1.0% 1.9% 2.0% 0.0% 0.0% 0.0% 
3. Eat with some help 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. Unable to eat by myself 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Unable to eat at all 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




Table 9B: 15D scores for the sixth dimension (eat) for breast cancer patients (n=130). 
Eating 
 WebChoice (n=55) Control (n=75) 
 Baseline* 6 months 12 months* Baseline 6 months 12 months 
Valid responses 54 55 54 75 75 75 
1. Eat normally 98.2% 96.4% 98.1% 100.0% 100.0% 100.0% 
2. Eat with minor difficulty 1.8% 3.6% 1.9% 0.0% 0.0% 0.0% 
3. Eat with some help 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. Unable to eat by myself 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Unable to eat at all 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.241 0.096 0.237    
Table 9C: 15D scores for the sixth dimension (eat) for prostate cancer patients (n=104). 
Eating 
 WebChoice (n=49) Control (n=55) 
 Baseline 6months 12 months* Baseline 6 months 12months 
Valid responses 49 49 48 55 55 55 
1. Eat normally 100.0% 100.0% 97.9% 100.0% 100.0% 100.0% 
2. Eat with minor difficulty 0.0% 0.0% 2.1% 0.0% 0.0% 0.0% 
3. Eat with some help 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. Unable to eat by myself 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Unable to eat at all 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) Equal equal 0.282    
For the dimension eating, there were some differences between the WebChoice groups and 
the control groups, in that the WebChoice groups for both cancer groups had a higher level 
of worse conditions (tables 9 A, B and C). However, the differences were not statistically 
significant.  
Table 10A: 15D scores for the eighth dimension (elimination) for all patients (n=234) 
Elimination 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months* Baseline* 6 months* 12 months 
Valid responses 104 104 103 129 129 130 
1.Bladder/bowel work normally 51.9% 50.0% 49.5% 51.9% 64.3% 53.8% 
2.Slight problems with 
bladder/bowel 
41.3% 41.3% 42.7% 46.5% 31.0% 43.8% 
3.Marked problems with 
bladder/bowel  
4.8% 5.8% 5.8% 1.6% 2.3% 0.8% 
4.Serious problems with 
bladder/bowel 
1.0% 1.0% 1.0% 0.0% .8% 0.8% 
5.No control over bladder/bowel 1.0% 1.9% 1.0% 0.0% 1.6% 0.8% 
Chi-square test (p) 0.302 0.230 0.270    
Table 10B: 15D scores for the eighth dimension (elimination) for breast cancer patients (n=130) 
Elimination 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months* Baseline* 6 months 12 months 
Valid responses 55 55 54 74 75 75 
1.Bladder/bowel work normally 67.3% 67.3% 68.5% 62.2% 76.0% 69.3% 
2.Slight problems with 
bladder/bowel 
30.9% 27.3% 31.5% 37.8% 24.0% 30.7% 
3.Marked problems with 
bladder/bowel  
1.8% 5.5% 0.0% 0.0% 0.0% 0.0% 
4.Serious problems with 
bladder/bowel 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5.No control over bladder/bowel 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.385 0.102 0.921    
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Table 10C: 15D scores for the eighth dimension (elimination) for prostate cancer patients (n=104) 
Elimination 
 WebChoice (n=49) Control (n=55) 
 Baseline 6 months 12 months Baseline 6 months* 12 months 
Valid responses 49 49 49 55 54 55 
1.Bladder/bowel works 
normally 
34.7% 30.6% 28.6% 38.2% 48.1% 32.7% 
2.Slight problems with 
bladder/bowel 
53.1% 57.1% 55.1% 58.2% 40.7% 61.8% 
3.Marked problems with 
bladder/bowel  
8.2% 6.1% 12.2% 3.6% 5.6% 1.8% 
4.Serious problems with 
bladder/bowel 
2.0% 2.0% 2.0% 0.0% 1.9% 1.8% 
5.No control over 
bladder/bowel 
2.0% 4.1% 2.0% 0.0% 3.7% 1.8% 
Chi-square test (p) 0.497 0.488 0.337    
For the dimension elimination, there were some differences between the WebChoice groups 
and the control groups, in that the WebChoice groups had a greater proportion of patients in 
the worse conditions than the control groups. The differences were not statistically 
significant (tables 10 A, B and C). 
Table 11A: 15D scores for the tenth dimension (mental function) for all patients (n=234) 
Mental function 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months Baseline 6 months* 12 months* 
Valid responses 104 104 104 130 129 129 
1.Think clearly and logically 70.2% 62.5% 62.5% 76.9% 72.1% 68.2% 
2.Slight difficulties thinking 
clearly and logically 
28.8% 34.6% 35.6% 23.1% 27.1% 30.2% 
3.Marked difficulties 
thinking clearly and logically 
1.0% 2.9% 1.0% 0.0% .8% 1.6% 
4.Great difficulties thinking 
clearly and logically 
0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 
5. Permanently confused 
and disoriented 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.308 0.189 0.535    
Table 11B: 15D scores for the tenth dimension (mental function) for breast cancer patients (n=130). 
Mental function 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months Baseline 6 months* 12 months 
Valid responses 55 55 55 75 74 75 
1.Think clearly and logically 60.0% 49.1% 54.5% 70.7% 64.9% 66.7% 
2.Slight difficulties thinking 
clearly and logically 
38.2% 45.5% 43.6% 29.3% 33.8% 30.7% 
3.Marked difficulties 
thinking clearly and logically 
1.8% 5.5% 0.0% 0.0% 1.4% 2.7% 
4.Great difficulties thinking 
clearly and logically 
0.0% 0.0% 1.8% 0.0% 0.0% 0.0% 
5. Permanently confused 
and disoriented 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




Table 11C: 15D scores for the tenth dimension (mental function) for prostate cancer patients (n=104). 
Mental function 
 WebChoice (n=49) Control (n=55) 
 Baseline 6 months 12 months Baseline 6 months 12 months* 
Valid responses 49 49 49 55 55 54 
1.Think clearly and logically 81.6% 77.6% 71.4% 85.5% 81.8% 70.4% 
2.Slight difficulties thinking 
clearly and logically 
18.4% 22.4% 26.5% 14.5% 18.2% 29.6% 
3.Marked difficulties 
thinking clearly and logically 
0.0% 0.0% 2.0% 0.0% 0.0% 0.0% 
4.Great difficulties thinking 
clearly and logically 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Permanently confused 
and disoriented 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.599 0.588 0.551    
For the dimension mental function, there were some differences between the WebChoice 
groups and the control groups, in that the WebChoice groups had a greater proportion of 
patients in the worse conditions than the control groups (tables 11 A, B and C). The 
difference was most present in the breast cancer group. The differences were not statistically 
significant.  
Table 12A: 15D scores for the eleventh dimension (discomfort and symptoms) for all patients (n=234). 
Discomfort and symptoms 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months Baseline 6 months* 12 months* 
Valid responses 104 104 104 130 129 129 
1.No physical discomfort or 
symptoms 
46.2% 43.3% 51.9% 41.5% 48.1% 46.5% 
2.Mild physical discomfort or 
symptoms 
43.3% 45.2% 35.6% 50.8% 42.6% 38.0% 
3.Marked physical 
discomfort or symptoms 
10.6% 9.6% 8.7% 7.7% 8.5% 14.7% 
4.Severe physical discomfort 
or symptoms 
0.0% 1.0% 3.8% 0.0% 0.0% 0.8% 
5.Unbearable physical 
discomfort or symptoms  
0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 
Chi-square test (p) 0.472 0.788 0.192    
Table 12B: 15D scores for the eleventh dimension (discomfort and symptoms) for breast cancer patients 
(n=130). 
Discomfort and symptoms 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months Baseline 6 months* 12 months* 
Valid responses 55 55 55 75 74 74 
1.No physical discomfort or 
symptoms 
40.0% 40.0% 43.6% 33.3% 48.6% 41.9% 
2.Mild physical discomfort or 
symptoms 
45.5% 41.8% 38.2% 56.0% 39.2% 41.9% 
3. .Marked physical 
discomfort or symptoms 
14.5% 14.5% 12.7% 10.7% 10.8% 14.9% 
4.Severe physical discomfort 
or symptoms 
0.0% 1.8% 5.5% 0.0% 0.0% 1.4% 
5.Unbearable physical 
discomfort or symptoms  
0.0% 1.8% 0.0% 0.0% 1.4% 0.0% 




Table 12C: 15D scores for the eleventh dimension (discomfort and symptoms) for prostate cancer 
patients (n=104). 
Discomfort and symptoms 
 WebChoice (n=49) Control (n=55) 
 Baseline 6  months 12 months Baseline 6 months 12 months 
Valid responses 49 49 49 55 55 55 
1.No physical discomfort or 
symptoms 
53.1% 46.9% 61.2% 52.7% 47.3% 52.7% 
2.Mild physical discomfort 
or symptoms 
40.8% 49.0% 32.7% 43.6% 47.3% 32.7% 
3. Marked physical 
discomfort or symptoms 
6.1% 4.1% 4.1% 3.6% 5.5% 14.5% 
4.Severe physical 
discomfort or symptoms. 
0.0% 0.0% 2.0% 0.0% 0.0% 0.0% 
5.Unbearable physical 
discomfort or symptoms  
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.826 0.943 0.221    
For the dimension discomfort and symptoms, there was almost no difference between the 
WebChoice and the control groups (tables 12 A, B and C). A tendency was that the 
WebChoice groups scored slightly higher at the best condition. This was especially present 
for the prostate cancer group. There were no statistically significant differences. 
Table 13A: 15D scores for the thirteenth dimension (distress) for all patients (n=234). 
Distress 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months Baseline 6 months* 12 months* 
Valid responses 104 104 104 130 129 129 
1. Not at all anxious 44.2% 44.2% 46.2% 49.2% 48.1% 51.2% 
2. Slightly anxious 46.2% 47.1% 42.3% 42.3% 41.9% 40.3% 
3. Moderately anxious 7.7% 6.7% 11.5% 8.5% 7.8% 6.2% 
4. Very anxious 1.9% 1.9% 0.0% 0.0% 2.3% 2.3% 
5. Extremely anxious 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.385 0.881 0.197    
Table 13B: 15D scores for the thirteenth dimension (distress) for breast cancer patients (n=130). 
Distress 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months Baseline 6 months* 12 months* 
Valid responses 55 55 55 75 74 74 
1. Not at all anxious 36.4% 32.7% 40.0% 48.0% 40.5% 50.0% 
2. Slightly anxious 52.7% 56.4% 50.9% 45.3% 47.3% 43.2% 
3. Moderately anxious 7.3% 9.1% 9.1% 6.7% 8.1% 5.4% 
4. Very anxious 3.6% 1.8% 0.0% 0.0% 4.1% 1.4% 
5. Extremely anxious 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.251 0.666 0.485    
Table 13C: 15D scores for the thirteenth dimension (distress) for prostate cancer patients (n=104). 
Distress 
 WebChoice (n=49) Control (n=55) 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 49 49 55 55 55 
1. Not at all anxious 53.1% 57.1% 53.1% 50.9% 58.2% 52.7% 
2. Slightly anxious 38.8% 36.7% 32.7% 38.2% 34.5% 36.4% 
3. Moderately anxious 8.2% 4.1% 14.3% 10.9% 7.3% 7.3% 
4. Very anxious 0.0% 2.0% 0.0% 0.0% 0.0% 3.6% 
5. Extremely anxious 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.892 0.655 0.378    
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For the dimension distress, there were no statistically significant differences between the two 
groups (tables 13 A, B and C). 
Table 14A: 15D score for the fourteenth dimension (vitality) for all patients (n=234). 
Vitality 
 WebChoice (n=104) Control (n=130) 
 Baseline 6 months 12 months* Baseline* 6 months 12 months* 
Valid responses 104 104 103 129 130 129 
1. Healthy and energetic 30.8% 29.8% 25.2% 31.8% 35.4% 36.4% 
2. Slightly weary 51.9% 40.4% 53.4% 52.7% 47.7% 45.0% 
3. Moderately weary 11.5% 20.2% 9.7% 15.5% 11.5% 16.3% 
4. Very weary 5.8% 8.7% 11.7% 0.0% 5.4% 2.3% 
5. Extremely weary 0.0% 1.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.043 0.184 0.005    
Table 14B: 15D scores for the fourteenth dimension (vitality) for breast cancer patients (n=130). 
Vitality 
 WebChoice (n=55) Control (n=75) 
 Baseline 6 months 12 months* Baseline* 6 months 12months* 
Valid responses 55 55 54 74 75 74 
1. Healthy and energetic 23.6% 23.6% 27.8% 29.7% 41.3% 44.6% 
2. Slightly weary 49.1% 34.5% 44.4% 54.1% 42.7% 40.5% 
3. Moderately weary 16.4% 27.3% 7.4% 16.2% 8.0% 12.2% 
4. Very weary 10.9% 12.7% 20.4% 0.0% 8.0% 2.7% 
5. Extremely weary 0.0% 1.8% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.034 0.012 0.005    
Table 14C: 15D scores for the fourteenth dimension (vitality) for prostate cancer patients (n=104). 
Vitality 
 WebChoice (n=49) Control (n=55) 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49  49 49 55 55 55 
1. Healthy and energetic 38.8% 36.7% 22.4% 34.5% 27.3% 25.5% 
2. Slightly weary 55.1% 46.9% 63.3% 50.9% 54.5% 50.9% 
3. Moderately weary 6.1% 12.2% 12.2% 14.5% 16.4% 21.8% 
4. Very weary 0.0% 4.1% 2.0% 0.0% 1.8% 1.8% 
5. Extremely weary 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.377 0.617 0.537    
For the dimension vitality, there were some differences between the WebChoice groups and 
the control groups, in that the WebChoice groups had a greater proportion of patients in the 
worse conditions than the control groups (tables 14 A, B and C). This difference was 
statistically significant for the breast cancer group, but not for the prostate cancer group. 
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Table 15A: 15D scores for the fifteenth dimension (sexual activity) for all patients (n=234). 
Sexual activity 
 WebChoice (n=104) Control (n=130) 
 Baseline*** 6 months* 12 months*** Baseline* 6 months** 12 months 
Valid responses 101 103 99 129 128 130 
1. Health has no 
adverse effect on 
16.8% 14.6% 11.1% 15.5% 18.0% 19.2% 
2. Health has slight 
effect on 
24.8% 19.4% 23.2% 37.2% 31.2% 26.2% 
3. Health has 
considerable effect on 
28.7% 33.0% 27.3% 27.1% 23.4% 25.4% 
4. Health makes sex 
almost impossible 
9.9% 7.8% 11.1% 5.4% 7.0% 9.2% 
5. Health makes sex 
impossible 
19.8% 25.2% 27.3% 14.7% 20.3% 20.0% 
Chi-square test (p) 0.260 0.197 0.392    
Table 15B: 15D scores for the fifteenth dimension (sexual activity) for breast cancer patients (n=130). 
Sexual activity 
 WebChoice (n=55) Control (n=75) 
 Baseline** 6 months 12 months*** Baseline* 6 months 12 months 
Valid responses 53  55 52 74 75 75 
1. Health has no 
adverse effect on 
30.2% 25.5% 21.2% 23.0% 29.3% 33.3% 
2. Health has slight 
effect on 
37.7% 36.4% 44.2% 51.4% 45.3% 42.7% 
3. Health has 
considerable effect on 
24.5% 32.7% 26.9% 25.7% 24.0% 21.3% 
4. Health makes sex 
almost impossible 
5.7% 1.8% 3.8% 0.0% 1.3% 1.3% 
5. Health makes sex 
impossible 
1.9% 3.6% 3.8% 0.0% 0.0% 1.3% 
Chi-square test (p) 0.113 0.350 0.452    
Table 15C: 15D scores for the fifteenth dimension (sexual activity) for prostate cancer patients (n=104). 
Sexual activity 
 WebChoice (n=49) Control (n=55) 
 Baseline* 6 months* 12 months** Baseline 6 months** 12 months 
Valid responses 48 48 47 55 53 55 
1. Health has no 
adverse effect on 
2.1% 2.1% 0.0% 5.5% 1.9% 0.0% 
2. Health has slight 
effect on 
10.4% 0.0% 0.0% 18.2% 11.3% 3.6% 
3. Health has 
considerable effect on 
33.3% 33.3% 27.7% 29.1% 22.6% 30.9% 
4. Health makes sex 
almost impossible 
14.6% 14.6% 19.1% 12.7% 15.1% 20.0% 
5. Health makes sex 
impossible 
39.6% 50.0% 53.2% 34.5% 49.1% 45.5% 
Chi-square test (p) 0.699 0.166 0.548    
For the dimension sexual activity, there were some differences between the WebChoice 
groups and the control groups, in that the WebChoice groups had a greater proportion of 
patients in the worse conditions than the control groups (tables 15 A, B and C).The 
differences were not statistically significant.  
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Summary of the eight relevant dimensions 
There was a tendency that the control group had a slightly higher quality of life than the 
WebChoice group for both cancer groups, but the difference was significant only for the 
fourteenth dimension, vitality (Tables 8A – 15C). The significantly different result is both 
present in the comparison of all patients and in the comparison within the breast cancer 
group. 
3.2.2 Analysis of the 15D index 
In the table below (table 16A), the mean index for each group of patients and each group of 
intervention is presented.  
Table 16 A: Mean (SD) 15D scores at 0, 6 and 12 months according to cancer type and intervention type 
(n = 234) 





Control (n=75)  WebChoice (n=49) Control (n=55)  
Baseline 0.85 (0.09) 0.88 (0.07) 0.059 0.87 (0.08) 0.87 (0.08) 0.882 
6 months 0.84 (0.10) 0.88 (0.10) 0.032 0.85 (0.08) 0.86 (0.08) 0.864 
12 months 0.85 (0.10) 0.88 (0.09) 0.131 0.84 (0.10) 0.84 (0.10) 0.801 
For the breast cancer group, the 15D index was slightly lower in the WebChoice group than 
in the control group at baseline, 6 months and 12 months, but the difference was statistically 
significant only at 6 months. For the prostate cancer group there was no difference at any 
point in time.  
A comparison of respondents and non-respondents according to 15D summary scores 
at baseline is given in the table below (table 16B). 
Table 16 B: Mean (SD) 15D-scores at baseline for patients who responded to the 15D-questionnaire all 
three times (n=234) and those who answered less than three times (n=91) 
 Breast (n=189) Prostate (n=136) 
 Answered all 
(n=130) 
Not answered all 
(n=59) 
p-value Answered all 
(n=104) 
Not answered all 
(n=32) 
p-value 
Baseline 0.87 0.84 0.043 0.87 0.85 0.104 
The breast cancer patients who answered less than three times had a statistically significant 
lower 15D-score at baseline. The same difference is a tendency for the prostate cancer 
patients.  
Time since diagnosis 
In the table below (table 17), the mean index for each group of patients and each group of 
intervention according to the second variable of time of diagnosis, are presented.  
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Table 17: Mean (SD) 15D scores at 0, 6 and 12 months according to cancer type, intervention type and 
time since diagnosis  
Months 
follow-up 
Breast cancer Prostate cancer 

















Baseline .87 (.06) .85 (.10) .87 (.08) .88 (.07) .85 (.11) .87 (.08) .92 (.03) .87 (.08) 
6 months .85 (.09) .84 (.10) .90 (.11) .87 (.09) .85 (.11) .85 (.08) .92 (.07) .85 (.08) 
12months .90 (.05) .85 (.10) .88 (.14) .88 (.09) .81 (.06) .84 (.10) .85 (.12) .83 (.09) 
When “new” and “old” breast cancer WebChoice groups are compared, there were some 
differences between the two groups in that the “new” WebChoice group had higher 15D 
score than the “old”. The opposite was present for the prostate cancer patients within the 
WebChoice groups. When comparing WebChoice and control groups, the WebChoice breast 
cancer patients with a recent diagnosis had a better score than those in the control group at 
12 months. At 6 months, the difference was opposite in the same patient group. The opposite 
was present for the prostate cancer patients within the WebChoice groups compared to the 
control group. 
Variables impact on the 15D index score 
The table below (table 18) shows the effect of independent variables on 15D summary score 
at 12 months. Type of intervention (WebChoice versus control) and baseline 15D summary 
score were entered as independent variables. 
Table 18: Linear regression analysis of the 15D score at 12 months 
 Unstandardised Coefficients B p-value 
Constant 0.170 0.001 
Intervention group 0.000 0.932 
15Dscore at baseline 0.789 0.000 
Type of intervention group had almost no impact on the 15D-score at 12 months, and it was 
not significant. The 15D score at baseline had much effect of the outcome of the 15D score 
at 12 months, and it was statistically significant.  
In an additional linear regression analysis of the 15D summary score at 12 months, 
time since diagnosis was added as independent variable (table 19).  
Table 19: Linear regression analysis of 15D summary score at 12 months 
 Unstandardised Coefficients B p-value 
Constant 0.169 0.001 
Intervention group 0.001 0.921 
15Dscore at baseline 0.779 0.000 
0-6 months 0.013 0.492 
7-12 months 0.021 0.147 
13-18 months  0.014 0.196 
19+ months (reference) 0  
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Time since diagnosis had no impact on the 15D summary score. The 15D summary score at 
baseline was the only variable which was statistically significant, and implicitly affected the 
dependent variable.   
3.2.3 QALYs 
For each patient, the one year of QALYs was calculated using linear interpolation combined 
with regression-based adjustment, which adjusts for baseline differences. In linear regression 
of one year QALY, baseline 15D score and type of intervention were used as explanatory 
variables (table 20) (Manca, 2005). QALY was the dependent variable.  
Table 20: Linear regression of one year QALYs 
 Unstandardised Coefficients B p-value 
Constant 0.131 0.000 
Intervention group  
(WebChoice = 1, control = 0) 
-0.004 
0.478 
Patient group  
(prostate cancer =1, breast cancer = 0) 
-0.013 
0.035 
15D score at baseline 0.848 0.000 
There was a very small and negative impact of WebChoice on the one year QALY value 
(table 20). 
QALYs gained for the WebChoice group according to cancer groups is presented in 
the table below (table 21). The difference of one year QALYs were analysed with t-test for 
each disease type separately.  
Table 21: The mean QALYs adjusted for baseline differences, for each cancer group according to type of 
intervention, and QALYs gained for the WebChoice group.  
 Breast cancer Prostate cancer  
 WebChoice 
(n=55) 
Control (n=75) p- value WebChoice   
(n= 49) 
Control (n=55) p- value 
QALY 0.8490 0.8767 0.028 0.8775 0.8834 0.650 
QALYs gained - 0.028  - 0.006  
The difference in QALYs was statistically significant for the breast cancer group, with a 
negative gain of QALYs (in the WebChoice group). There was no difference within the 
prostate cancer group. 
QALYs gained for the WebChoice group for both cancer groups is presented in the 
table below (table 22). 
Table 22: The mean QALYs adjusted for baseline differences for both cancer group according to type of 
intervention, and QALYs gained for the WebChoice group. 
 Both cancer groups 
 WebChoice Control p- value 
QALY 0.8624 0.8795 0.060 
QALYs gained - 0.017  
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The difference between the WebChoice group and control group in QALYs was not 
statistically significant.  
Variables’ impact on QALYs 
Finally, the one year 15D summary scores were analysed as dependent variable in a linear 
regression, where intervention group, patient group, 15D score at baseline, age and time 
since diagnosis were independent variables (table 23). The variables’ impact on QALYs are 
tested in the table below. 
Table 23: The variables intervention group, patient group, 15D score at baseline, age and time since 
diagnosis impact on QALYs.  
 Unstandardised Coefficients B p-value 
Constant 0.134 0.000 
Intervention group  
(WC=1, C=0) 
-0.004 0.540 
Patient group (PC=1, 
BC=0) 
-0.016 0.059 
15Dscore at baseline 0.837 0.000 
Age 0.00 0.810 
0-6 months 0.012 0.289 
7-12 months 0.010 0.264 
13-18 months - 0.001 0.876 
19+ months (reference) 0  
The one year QALY was slightly lower in the prostate cancer group, while age and time 
since diagnosis had no impact. 15D score at baseline was the only variable which was 
statistically significant.  
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4. Discussion 
The results in the previous section seem to indicate that WebChoice has very little, if any, 
impact on HRQOL for cancer patients. However, such a conclusion does not take the 
strengths and weaknesses of this study into consideration. This section is first and foremost a 
discussion of core aspects of internal and external validity: Are there any systematic errors in 
the study that have influenced the results (internal validity), and can the results be applied to 
the population (external validity) (Thelle, 2002)?   
4.1 Strenghts 
The research team applied a well tested method and measurement index to gain knowledge 
about the effects of WebChoice. When choosing a randomised controlled trial to investigate 
the effect, the study both gained control of cause and effect and a low risk of selection bias 
since patients are assigned to type of intervention by chance. Other types of study designs 
would not have given the same degree of control (see section 1.6 Epidemiology and study 
design). As in all surveys the problem of bias is still inherent, an aspect which is discussed 
later under representativeness.  
15D is a sensitive instrument which measures several relevant aspects that affect the 
HRQOL for a person. The use of this instrument gives a good and valid measurement of the 
patients’ health conditions. The algorithm for the index is validated both in Finland and in 
Denmark, and these countries have approximately the same population composition  as 
Norway according to age, health level and so on. This indicates that it should be valid to 
employ the 15D index on Norwegian patients.  
Randomisation 
The randomisation of the patients in general was good. Differences in demographics were 
small, but there was a specific problem for the breast cancer group at baseline: The 
WebChoice group had lower HRQOL than the control group. This could imply that the 
randomisation process was unsuccessful. The baseline problem has been compensated for in 
the final analysis.  
The variable time since diagnosis was almost equally distributed, but a trend was that 
the WebChoice group consisted of a few more patients with more recent diagnoses, though it 
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was not significant. A regression analysis showed that this variable had little or no effect on 
the HRQOL after twelve months. Hence, the difference had little impact on the study since 
more than 80 percent of the participants have had the diagnosis for more than one year. 
4.2 Weaknesses 
4.2.1 Characteristics 
What characterises the respondents? This is both a question relevant for evaluating 
representativeness and to determine whether or not there are some special characteristics of 
the sample which makes the results not valid for patients with other characteristics (for 
different types of bias – see section 1.6 Epidemiology and study design). The latter is the 
concern of this section, and representativeness will be discussed later.   
Socio-economic charateristics  
The respondents who answered all three times had the following characteristics that can be 
compared with statistics on the Norwegian population in general.   
The respondents were well educated: Approximately 60 percent (breast) and 70/50 
percent (prostate intervention/control group) of the respondents had a college degree or more 
(table 4). In 2007, 25 percent of the Norwegian population had a college degree or more 
(Utdanningsnivå i befolkningen, 2009). This must of course be adjusted for age, but the 
result is quite the same: 27 percent of the Norwegian population above 30 years had a 
college degree or more in 2007.     
The respondents had medium to high income: Approximately 70 percent of the 
respondents had a household income of 400 000 NOK or more (table 4). In 2007, the median 
household income in Norway was 366 000 NOK (Inntekt, 2009). 
Education and income are indicators of skills concerning gathering and coping with 
complex information, so the characteristics could indicate high levels of skills in the sample. 
This is relevant since WebChoice is a tool for providing patients with information on their 
own disease. The special characteristic of the respondents implies that results in this study do 
not necessarily apply to patients with little or no education and/or low income.  
Time since diagnosis 
The recruitment problems led the research team to omit one important inclusion criterion 
first stated in the protocol: Time since diagnosis must be within the last 12 months. The 
consequence of omitting this criterion was a quite different sample than originally planned: 
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More than 70 percent of the participants who joined have had the diagnosis for more than 
one year (table 6).  
Since cancer patients are in a situation with a high information need and are often 
intensively seeking information, it is relevant that most of the participants were well 
experienced with their own disease (Luker et al., 1995). Most of the respondents had 
received the diagnosis for more than twelve months ago, which probably gave them time to 
gain extensive information. Most likely, there is a difference between being unfamiliar and 
inexperienced with the disease and its consequences, and being a patient who has had time to 
get information and experience. To put inexperienced and experienced patients in the same 
trial without the necessary numbers to make sub-analyses, is to mix two groups that could be 
incomparable. The consequence is that this study primarily concerns patients with 
experience and therefore with knowledge on their own disease, and hence the results cannot 
necessarily be applied to patients with a recent diagnosis.  
Health 
The respondents had a 15D-score at baseline of approximately 0.85 (table 16 B). Could it be 
that the respondents only to a limited extent suffered from burdens of the disease? The 15D 
score implies that many respondents had set their health states at level 1 or 2 for many of the 
dimensions, at baseline. A control analysis shows that the average level for almost all of the 
dimensions is between 1 and 2 (see Appendix). The first two levels in each dimension are 
typically described as “no problems” or “minor problems”. From this, it is possible to 
assume that the patients only to a limited extend suffered from the problems related to the 
disease. WebChoice addresses problems for many different health states and problems, so 
the results are not necessarily valid for patients who suffer severe problems from the disease. 
4.2.2 Representativeness 
Do the respondents differ from the population of breast- and prostate cancer patients in 
Norway? Internal validity of this study is threatened by various types of selection bias and 
few participants. The problem with selection bias and few participants is that the sample may 
not represent the population it was supposed to represent and therefore have a weakened 
external validity. 
The characteristics of the sample should be compared with the population (breast 
cancer and prostate cancer patients) to determine representativeness. A full scale comparison 
of the characteristics requires an extensive gathering and adapting of statistical findings of 
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others, which would be beyond the scope of this thesis. However, the following 
considerations concerning representativeness of the characteristics can still be made: 
When it comes to age, the respondents are middle aged: approximate mean ages are 
50 years and 65 years (breast/prostate). As outlined in section 1, these cancer types typically 
strikes at middle age, so the sample appears to be representative in this aspect. However, it 
could be that the respondents had an overrepresentation of “younger” patients. 
The representativeness of the patients’ education and income is difficult to measure. I 
have no directly comparable data on educational and income levels for prostate cancer and 
breast cancer patients, but high levels of education increases the risk of both prostate cancer 
and breast cancer (Kreft, 2009 and Green et al., 2005). This implies that persons with 
education above the national average could be overrepresented for both cancer types. The 
overrepresentation of persons with high education in the sample indicates that the sample 
probably is representative for the population under study.  
I have not been able to find any average on time since diagnosis for breast cancer and 
prostate cancer patients under treatment, so the representativeness of the sample concerning 
this aspect cannot be exactly measured. However, the survival rate is high (over 80 percent) 
after five years since diagnosis for both cancer types (Prostatakreft, 2009 and Småstuen et 
al., 2008). This could indicate that many prostate cancer and breast cancer patients have had 
their diagnosis for an extended period of time. Hence, the overweight of respondents with 
old diagnosis does not necessarily lower the representativeness of the sample.  
To my knowledge, there is little data on the average HRQOL score for breast cancer 
and prostate cancer patients in Norway. A comparison of the health of the respondents in 
sample and the population is therefore not possible.  
Recruitment  
The research team was unable to collect the pre-planned and desired number of participants. 
While this should be kept in mind when dealing with the results, the number of respondents 
is still high enough for a valid analysis. Unfortunately, it is not high enough for sub-
analyses.  
The respondents joined through advertisements, and the recruitment process could 
have impact on the representativeness of the group. Self-recruitment tends to favour those 
who have a special interest in the subject (Chambelis & Schutt, 2006). This is a common 
problem for many surveys. The self-recruitment could in itself have lead to a selection bias, 
because certain types of persons could be more eager to join the study than others. The 
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recruitment problems led the research team to repeat the same recruitment procedure several 
times, and this may have led to an increased number of “special-interest” respondents 
(Chambelis & Schutt 2006). 
Another aspect of self-recruitment of patients is the risk of recruiting only those with 
relatively good health. Cancer patients have a potentially life threatening disease, and not all 
have the mental and/or physical energy needed to join a survey. Self-recruitment requires 
initiative from the patient, and those with bad health could be less likely to join. Experienced 
patients may also find it easier to participate in a survey, since they probably have had time 
to deal with some of the mental trauma of the diagnosis. 
It should also be mentioned that Internet access was an inclusion criterion that could 
have excluded some patients from joining the survey. In Norway, 84 percent of all 
households had Internet access in 2008 (IKT i husholdningene, 2008). Since some of the 
population in Norway does not have access to Internet, the inclusion criterion could lead to a 
selection bias. Patients with Internet access, but other operative systems than Microsoft 
Windows, were also excluded, which could have created another selection bias. However, it 
is hard to see how this could have had any impact on the results. 
Dropout 
Dropout was a problem during the trial period. Especially during the period from 0 to 6 
months, the number of patients who dropped out was relatively high (figure 5). A problem 
with high dropout rates is selection bias. In addition, the matter that patients were not 
obliged to reveal the reason why they dropped out, could make it harder to detect a possible 
selection bias.  
27 percent of the respondents dropped out from inclusion to baseline. It could be a 
number of reasons for this dropout, but there is no data on the 120 respondents who chose to 
leave the study. However, there is data on the dropouts of the next two rounds, and it is 
likely that the same mechanisms took place all three times.  
In total, 234 of 445 patients filled out the 15D questionnaire all three times. This 
gives an answer rate of 53 percent and a dropout rate of 47 percent. This is a high dropout 
rate, but it is as expected by the research team who predicted an attrition rate of 50 percent 
(Chambelis & Schutt, 2006). The patients who dropped out had a lower HRQOL score at 
baseline than the ones who answered the questionnaire all three times (table 16B). This 
difference was statistically significant for the breast cancer patients and a tendency for the 
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prostate cancer patients. This indicates that the dropout lead to an overrepresentation of 
patients with higher HRQOL scores. 
Socio-economic differences between respondents and dropouts must also be 
examined. In the breast cancer group (table 5A), differences in age, education and income 
points in different directions. In the breast cancer WebChoice group, the non-respondents 
were statistically significantly younger than the respondents. This was only a tendency in the 
control group. When it comes to income, it is somewhat unclear. In both groups, the non-
respondents were less represented with medium/high income, but on the other hand, more of 
them had high income. Education level was equally distributed between respondents and 
non-respondents in the WebChoice breast cancer group. This is not the case in the control 
group, where the non-respondents tended to be more educated. The socio-economic 
variables do not reveal a clear pattern of systematic differences with impact on the 
representativeness, or which can explain the dropout. 
The picture of the non-respondents is equally unclear in the prostate cancer group 
(table 5B). The non-respondents in the WebChoice group tended to be older, they had less 
education and they had lower household income than the respondents. In the control group, 
the non-respondents were statistically significantly younger, and they tended to have more 
education and higher household income. The latter difference was close to statistically 
significant. Socio-economic differences are opposite between non-respondents in the 
WebChoice and in the control group. Why well educated and high income individuals drop 
out of the control group remains unanswered, but a plausible explanation on WebChoice 
non-respondents is that they find the web tool challenging due to their higher age and less 
extensive education. 
To sum up, health seems to be the only systematic difference between the non-
respondents and the respondents. A more difficult health situation may be the dropout reason 
for many of the participants. To fill out a questionnaire during the cancer could have been 
difficult, and to both fill out questionnaires and use a new web-tool, was perhaps simply too 
much. This corresponds with a higher dropout rate in the WebChoice group than in the 
control group for breast cancer patients. Socio-economic differences are not coherent when it 
comes to dropout and should be used with caution to explain the dropout or to lower the 
representativeness. 
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Concluding on representativeness 
As outlined above, the recruitment process could have led to respondents who have 
extensive knowledge on own disease and who have “minor” disease related problems. The 
dropout rate can be considered as high, and it may have led to a further concentration of 
patients with high HRQOL score. Both of these mechanisms make the sample less 
representative, but it is difficult to determine to what extent. In all, the sample is 
representative enough for a valid analysis with some reservations. The results in this study 
must be used with caution on patients with low HRQOL, as they could be underrepresented.  
It is difficult to judge whether or not this sample is representative for similar patients 
in other countries, but it is likely that an intervention such as WebChoice may be sensitive 
for cultural factors and differences in health care systems.     
4.2.3 Response 
Since fewer cancer patients than pre-planned were included in the study (445 versus 1000), 
the randomised controlled trial was underpowered according to number of participants (234 
versus 400). No power calculation was done for 15D, and the trial may have been 
underpowered for this endpoint. Underpowering may increase the risk of committing an 
error of type 2: There is a risk of neglecting a real difference between the WebChoice and 
control group because the number of patients was too low. However, the likelihood of a 
type-2 error seems small since there was not even a tendency for impact of WebChoice on 
the number of QALYs.  
Missing values made the 15D questionnaires incomplete, and they had to be replaced 
to calculate the 15D summary indexes. The number of missing values per questionnaire 
increased with time, and the sexual activity value had the most missing values. This could 
have an adverse effect on the result for prostate cancer patients, because this variable 
(together with the elimination variable) is probably the one which is most affected by 
prostate cancer, and because the functional problems often increase with time.  
A problem with replacing missing values is uncertainty. As more values are missing 
and are replaced, the more uncertain the 15D index becomes, which indicates the health-
related quality of life for the patient it concerns. There is a certain probability that the 
replaced value is not the true one. 
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4.3 The results 
4.3.1 The main result 
There was no difference in health-related quality of life between the WebChoice group and 
the control group, neither in the breast cancer group nor prostate cancer group.  
Little or no differences between the intervention and control groups are found when 
health related quality of life is transformed into QALYs. The intervention had no effect, 
since the only variable with significant impact on QALY was the 15D score at baseline. 
Other variables, such as time since diagnosis, cancer type and intervention type had only a 
minor and non-significant effect on the one-year number of QALYs.  
4.3.2 Other results and tendencies 
There was no statistically significant difference at twelve months for the 15D index, but 
there was a tendency that the WebChoice groups had a slightly lower HRQOL than the 
control groups. Especially the score that derives from the dimension vitality was statistically 
significant lower for the WebChoice groups.  
When split into the different cancer groups, the statistically significant difference 
only occurred for the breast cancer group, and it was statistically significant at all times. 
Other dimensions had nearly statistically significant different results, which pointed in the 
same direction for the breast cancer group. These were the dimensions eating, elimination 
and mental function. The differences can partly be explained by differences at baseline. The 
prostate cancer group had no statistically significant different results.  
Baseline differences were adjusted when calculating QALYs, but the results 
remained the same. The WebChoice breast cancer group had a statistically significant lower 
QALY than the control group. The difference was small. 
4.3.3 Possible explanations 
The results of this study do not confirm the main hypothesis, which was that 
WebChoice improves patients’ HRQOL. One possible interpretation of the study is that 
WebChoice in fact has no effect on cancer patients’ HRQOL. A premise for the main 
hypothesis, however, was that WebChoice provided new and relevant information, so there 
are several possible explanations as to why no difference was found between the two groups 
in this trial:  
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The patients were well experienced: Most of the patients included in the trial had 
received the diagnosis more than 12 months before inclusion. This could lower the impact of 
the intervention, because the patients have had an extended period of time to gain much of 
the knowledge accessible in WebChoice. For this group, the available information could 
already be known and therefore be “useless”. If WebChoice were to be tested on patients 
with a recent diagnosis, the effect on HRQOL could be positive. 
The patients had high competence: As outlined in the discussion on recruitment and 
dropout, the participants were both well educated and perhaps especially interested. 
Combined with their experience, the patients are likely to have already gained much of the 
information accessible in WebChoice, prior to the trial.   
The patients were of good health: The HRQOL for the patients was relatively high in 
general. Perhaps a large amount of the information and advice was not relevant and was 
intended for patients with more severe side-effects and symptoms. If WebChoice were tested 
on patients with more severe health problems, it is possible that the effect on HRQOL would 
be positive. 
Other explanations are more speculative. For instance, WebChoice could have both 
positive and negative effects that nullify each other: More knowledge about the disease 
could make cancer patients more anxious, because they become aware of what different 
treatments and what the cancer itself can do to their health. This explanation is unlikely, 
since there was almost no effect on any of the 15D values when they were analysed 
separately. 
4.4 Findings of others 
WebChoice is a new application designed to assist patients in symptom management, while 
previous network-based computerised home support systems have been more focused on 
improving self-efficacy. Several surveys concerning Internet-based support for outpatients 
with cancer or other diseases indicate a positive relationship with patients’ well-being and 
self-efficacy, but few of these surveys actually measure patients’ HRQOL.  
Internet support provides tailored and accessible information and more remote 
nursing services (Brennan, 2001). This correlates well with the findings in a previous study: 
Internet based support for HIV-positive patients improved quality of life, in terms of a more 
active life and less negative emotions (Gustafson, 1999). The patients were also more 
efficient in their use of health care services.  
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Significant improvements in psycho-social quality of life were also found in a survey 
studying online self-help groups for breast cancer patients (Lieberman & Goldstein, 2005).  
Two other studies conclude that access to information improved patients’ self-
efficacy and gave them more confidence to both ask questions and discuss treatment options 
with their physicians (Gustafson et al., 2001 and Fleischer, 2002). The patients became more 
involved in the decision-making process. The benefits were greatest for patients with less 
income and education (Gustafson et al., 2001).    
Gustafson et al. went deeper into the latter aspect in a survey concerning low-income 
women with breast cancer and the Internet-based eHealth System CHESS in the United 
States of America (Gustafson et al., 2005). Access to the system improved quality of life.  
The findings of Gustafson et al. (2001 and 2005) support the “high competence” 
explanation for no positive effects in this study of WebChoice. Demographic differences 
combined with differences in health care system also have an impact on the effect of online 
support. Free and accessible advice probably makes a statistically significant difference for a 
low income group with little education, in a high cost health care system. In this study, the 
situation is opposite: The participants are well educated, with medium to high income in a 
low-cost health care system.  
Patients in three of the mentioned surveys were all inexperienced in their situation, 
either with a new diagnosis or on recovery from an operation (Gustafsson et al., 2001, 
Fleischer, 2002 and Brennan, 2001). This is an important difference from the patients in this 
study of WebChoice, and it confirms that the results from this study are not necessarily valid 
for newly diagnosed patients.    
4.5 Conclusion 
The results of this study show that WebChoice had no effect on the patients’ health-related 
quality of life, and no QALYs were gained. Hence, the main hypothesis which stated that 
WebChoice improves the 15D summary score (index), can be rejected. The hypotheses for 
each of the eight dimensions can also be rejected, since no positive effects for WebChoice 
were found. 
However, these conclusions must be reached with some reservations: The results do 
not necessarily apply to patients with a recent diagnosis, to patients with little education or to 
patients with low HRQOL. 
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The respondents in this trial were well educated, well experienced with the disease 
and were of relatively good health. This indicates that the patients had probably gained much 
of the information accessible in WebChoice through different channels prior to the trial, and 
that some of the information was irrelevant. If another study tests WebChoice on patients 
with opposite characteristics than the respondents in this trial, the result could be a positive 
effect and a fundamentally different result from the one in this study.  
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Appendix 
Variables included in the trial 
Variable name Explanation Type 
ID  Patients unique ID number Numeric 
MTIME  Time at measurement Nominal 
GROUP Group assignment Numeric 
DATE Date of measurement  Date 
AGE Age Numeric 
MARITAL Marital status Nominal 
CHILD Number of children  Nominal 
ED Level of education Ordinal 
INCOME Household total yearly income Numeric 
DIA Cancer diagnosis Nominal 
TIMEDIA When diagnosis was given Date 
FIRSTDIA First diagnosis Nominal 
CBACK The cancer has returned Nominal 
METASTASIS Metastasis Nominal 
SURGERYuns First participants kind of surgery is not known Nominal 
REMbreast  Removed breast Nominal 





Surgery sparing breast Nominal 
RADIOTHbreast Radiotherapy breast and or lymphnodes Nominal 
CHEMObreast Chemotherapy Nominal 
ANTIHbreast Anti hormone treatment Nominal 
HERCEPTbreast  Herceptin Nominal 
REMPROprostate Removed prostate Nominal 
RADIOTHprostate Radiotherapy prostate Nominal 
HORMON_unspecified First participants kind of hormon is not known Nominal 
HORMTABprostate  Hormone treatment (tablets) Nominal 
HORMINJECTprostate Hormone treatment (injections) Nominal 
REMTESTprostate Removed testicles Nominal 
CHEMOprostate Chemotherapy Nominal 
OTHTREAT Other treatment for current cancer Nominal 
WHATTREAT What other treatment for current cancer  Nominal 
OTHERILL Other illnesses Nominal 
WHATILL What illnesses Nominal 
COMPEX Experience using computers  Ordinal 
15D: QL1mobil Mobility Ordinal 
15D: QL2sight Vision Ordinal 
15D: QL3hear Hearing Ordinal 
15D: QL4breath Breathing Ordinal 
15D: QL5sleep Sleeping Ordinal 
15D: QL6eat Eating Ordinal 
15D: QL7speech Speech Ordinal 
15D: QL8urin Elimination Ordinal 
15D: QL9activ Usual activities Ordinal 
15D: QL10ment Mental function Ordinal 
15D: QL11symp Discomfort and symptoms Ordinal 
15D: QL12depr Depression Ordinal 
15D: QL13stress Distress Ordinal 
15D: QL14qol Vitality Ordinal 
15D: QL15sex Sexual activity Ordinal 
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Uncommented 15D results 
1A: 15D scores for the first dimension for all patients (n= 234). 
Moving  
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 103 102 104 130 130 128 
1.Walk normally indoors and 
outdoors 
88.3% 84.3% 88.5% 89.2% 86.9% 82.8% 
2.Slight difficulties 
outdoors/stairs 
10.7% 14.7% 8.7% 10.8% 12.3% 14.8% 
3.Considerably difficulty 
outdoors/stairs 
1.0% 1.0% 2.9% 0.0% 0.8% 2.3% 
4. Walk indoors only with 
help 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5.Completely bed-ridden 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.531 0.852 0.350    
1B: 15D scores for the first dimension for breast cancer patients (n=130). 
Moving  
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 55 75 75 74 
1.Walk normally indoors and 
outdoors 
90.9% 87.3% 90.9% 92.0% 89.3% 86.5% 
2.Slight difficulties 
outdoors/stairs 
9.1% 12.7% 9.1% 8.0% 10.7% 12.2% 
3.Considerably difficulty 
outdoors/stairs 
0.0% 0.0% 0.0% 0.0% 0.0% 1.4% 
4. Walk indoors only with 
help 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Completely bed-ridden 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.825 0.716 0.581    
1C: 15D scores for the first dimension for prostate cancer patients (n=104). 
Moving  
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 48 47 49 55 55 54 
1.Walk normally indoors and 
outdoors 
85.4% 80.9% 85.7% 85.5% 83.6% 77.8% 
2.Slight difficulties 
outdoors/stairs 
12.5% 17.0% 8.2% 14.5% 14.5% 18.5% 
3.Considerably difficulty 
outdoors/stairs 
2.1% 2.1% 6.1% 0.0% 1.8% 3.7% 
4. Walk indoors only with 
help 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Completely bed-ridden 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




2A: 15D scores for the second dimension for all patients (n= 234). 
Vision 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 103 103 130 130 129 
1. Read without difficulty 93.3% 88.3% 87.4% 92.3% 90.0% 90.7% 
2. Read with slight difficulty 5.8% 10.7% 10.7% 7.7% 10.0% 8.5% 
3. Read with considerable 
difficulty 
1.0% 1.0% 1.9% 0.0% 0.0% .8% 
4. Cannot read, but can walk 
without guidance 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Almost or completely blind 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.457 0.521 0.621    
2B: 15D scores for the second dimension for breast cancer patients (n=130). 
Vision 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 55 75 75 74 
1. Read without difficulty 92.7% 87.3% 87.3% 92.0% 89.3% 90.5% 
2. Read with slight difficulty 7.3% 12.7% 9.1% 8.0% 10.7% 8.1% 
3. Read with considerable 
difficulty 
0.0% 0.0% 3.6% 0.0% 0.0% 1.4% 
4. Cannot read, but can walk 
without guidance 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Almost or completely blind 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.878 0.716 0.676    
2C: 15D scores for the second dimension for prostate cancer patients (n=104). 
Vision 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 48 48 55 55 55 
1. Read without difficulty 93.9% 89.6% 87.5% 92.7% 90.9% 90.9% 
2. Read with slight difficulty 4.1% 8.3% 12.5% 7.3% 9.1% 9.1% 
3. Read with considerable 
difficulty 
2.0% 2.1% 0.0% 0.0% 0.0% 0.0% 
4. Cannot read, but can walk 
without guidance 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Almost or completely blind 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.453 0.558 0.576    
3A: 15D scores for the third dimension for all patients (n= 234). 
Hearing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 103 104 130 130 129 
1. Hear speech normally 92.3% 88.3% 88.5% 91.5% 90.0% 89.1% 
2. Hear speech with a little 
difficulty 
7.7% 10.7% 11.5% 7.7% 9.2% 9.3% 
3. Hear speech with 
considerable difficulty 
0.0% 1.0% 0.0% 0.8% 0.8% 1.6% 
4. Hear even loud voices 
poorly 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5.Completely deaf 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




3B: 15D scores for the third dimension for breast cancer patients (n=130). 
Hearing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 55 75 75 74 
1. hear speech normally 98.2% 90.9% 94.5% 96.0% 93.3% 94.6% 
2. hear speech with a little 
difficulty 
1.8% 9.1% 5.5% 4.0% 6.7% 5.4% 
3. hear speech with 
considerable difficulty 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. Hear even loud voices poorly 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Completely deaf 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.477 0.608 0.990    
3C: 15D scores for the third dimension for prostate cancer patients (n=104). 
Hearing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 48 49 55 55 55 
1. hear speech normally 85.7% 85.4% 81.6% 85.5% 85.5% 81.8% 
2. hear speech with a little 
difficulty 
14.3% 12.5% 18.4% 12.7% 12.7% 14.5% 
3. hear speech with 
considerable difficulty 
0.0% 2.1% 0.0% 1.8% 1.8% 3.6% 
4. Hear even loud voices poorly 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Completely deaf 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.626 0.995 0.365    
4A: 15D scores for the fourth dimension for all patients (n= 234). 
Breathing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 102 104 129 130 128 
1. Breathe normally 60.6% 52.0% 49.0% 64.3% 52.3% 53.1% 
2. Shortness of breath during 
heavy work 
32.7% 41.2% 42.3% 28.7% 40.8% 34.4% 
3. Shortness of breath walking 
on flat ground 
3.8% 5.9% 6.7% 6.2% 5.4% 10.2% 
4. Shortness of breath after light 
activity 
1.9% 0.0% 1.9% .8% 1.5% 2.3% 
5. Breathing difficulties almost 
all the time 
1.0% 1.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.577 0.579 0.579    
4B: 15D scores for the fourth dimension for breast cancer patients (n=130). 
Breathing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 55 74 75 73 
1. Breathe normally 54.5% 47.3% 52.7% 64.9% 56.0% 56.2% 
2. Shortness of breath during 
heavy work 
36.4% 43.6% 40.0% 29.7% 37.3% 31.5% 
3. Shortness of breath walking 
on flat ground 
5.5% 9.1% 7.3% 5.4% 5.3% 11.0% 
4. Shortness of breath after 
light activity 
1.8% 0.0% 0.0% 0.0% 1.3% 1.4% 
5. Breathing difficulties almost 
all the time 
1.8% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.452 0.540 0.589    
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4C: 15D scores for the fourth dimension for prostate cancer patients (n=104). 
Breathing 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 47 49 55 55 55 
1. Breathe normally 67.3% 57.4% 44.9% 63.6% 47.3% 49.1% 
2. Shortness of breath during 
heavy work 
28.6% 38.3% 44.9% 27.3% 45.5% 38.2% 
3. Shortness of breath walking 
on flat ground 
2.0% 2.1% 6.1% 7.3% 5.5% 9.1% 
4. Shortness of breath after 
light activity 
2.0% 0.0% 4.1% 1.8% 1.8% 3.6% 
5. Breathing difficulties almost 
all the time 
0.0% 2.1% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.670 0.470 0.876    
5A: 15D scores for the dimension for all patients (n= 234). 
Speech 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 104 103 130 130 130 
1. Speak normally 94.2% 94.2% 92.2% 96.9% 93.1% 93.8% 
2. Slight speech difficulties 5.8% 5.8% 7.8% 3.1% 6.9% 6.2% 
3. Can make myself 
understood 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. People have great difficulty 
understanding my speech 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Only make myself 
understood by gestures 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.312 0.720 0.629    
5B: 15D scores for the seventh dimension for breast cancer patients (n=130). 
Speech 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 54 75 75 72 
1 Speak normally 92.7% 92.7% 96.0% 94.7% 90.7% 96.0% 
2. Slight speech difficulties 7.3% 7.3% 4.0% 5.3% 9.3% 4.0% 
3. Can make myself understood 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. People have great difficulty 
understanding my speech 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Only make myself understood 
by gestures 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.649 0.677 0.222    
5C: 15D scores for the seventh dimension for prostate cancer patients (n=104). 
Speech 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 47 47 49 55 55 55 
1. Speak normally 95.9% 95.9% 93.9% 100.0% 96.4% 90.9% 
2. Slight speech difficulties 4.1% 4.1% 6.1% 0.0% 3.6% 9.1% 
3. Can make myself understood 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
4. People have great difficulty 
understanding my speech 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
5. Only make myself understood 
by gestures 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




6A: 15D scores for the dimension for all patients (n= 234). 
Usual activities 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 104 103 129 129 130 
1 Perform my usual activities 43.3% 50.0% 49.5% 47.3% 51.2% 51.5% 
2. Perform usual activities with 
minor difficulty 
37.5% 31.7% 35.0% 41.9% 34.9% 34.6% 
3. Usual activites with 
considerable difficulty 
13.5% 11.5% 5.8% 5.4% 10.9% 9.2% 
4. Small proportion of usual 
activities 
5.8% 6.7% 8.7% 5.4% 3.1% 4.6% 
5. None of my usual activities 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.202 0.611 0.450    
6B: 15D scores for the seventh dimension for breast cancer patients (n=130). 
Usual activities 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 55 55 75 74 75 
1 Perform my usual activities 32.7% 40.0% 43.6% 41.3% 54.1% 52.0% 
2. Perform usual activities with 
minor difficulty 
36.4% 34.5% 32.7% 45.3% 31.1% 37.3% 
3. Usual activites with 
considerable difficulty 
21.8% 16.4% 10.9% 6.7% 10.8% 5.3% 
4. Small proportion of usual 
activities 
9.1% 9.1% 12.7% 6.7% 4.1% 5.3% 
5. None of my usual activities 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.070 0.328 0.264    
6C: 15D scores for the seventh dimension for prostate cancer patients (n=104). 
Usual activities 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 49 48 54 55 55 
1. Perform my usual activities 55.1% 61.2% 56.2% 55.6% 47.3% 50.9% 
2. Perform usual activities with 
minor difficulty 
38.8% 28.6% 37.5% 37.0% 40.0% 30.9% 
3. Usual activites with 
considerable difficulty 
4.1% 6.1% .0% 3.7% 10.9% 14.5% 
4. Small proportion of usual 
activities 
2.0% 4.1% 4.2% 3.7% 1.8% 3.6% 
5. None of my usual activities 0.0% 0.0% 2.1% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.965 0.382 0.072    
7A: 15D scores for the twelfth dimension for all patients (n= 234). 
Depression 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 104 103 104 130 128 129 
1. Not at all sad 43.3% 46.6% 51.0% 48.5% 53.9% 52.7% 
2. Slightly sad 48.1% 41.7% 39.4% 45.4% 35.9% 35.7% 
3. Moderately sad 7.7% 10.7% 8.7% 5.4% 4.7% 10.1% 
4. Very sad 1.0% 1.0% 1.0% .8% 5.5% 1.6% 
5. Extremely sad 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




7B: 15D scores for the twelfth dimension for breast cancer patients (n=130). 
Depression 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 55 54 55 75 74 74 
1 Not at all sad 36.4% 35.2% 45.5% 50.7% 50.0% 52.7% 
2 Slightly sad 52.7% 53.7% 47.3% 44.0% 37.8% 33.8% 
3. Moderately sad 9.1% 11.1% 7.3% 4.0% 2.7% 12.2% 
4. Very sad 1.8% 0.0% 0.0% 1.3% 9.5% 1.4% 
5. Extremely sad 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Chi-square test (p) 0.341 0.007 0.351    
7C: 15D scores for the twelfth dimension for prostate cancer patients (n=104). 
Depression 
 WebChoice Controls 
 Baseline 6 months 12 months Baseline 6 months 12 months 
Valid responses 49 49 49 55 54 55 
1 Not at all sad 51.0% 59.2% 57.1% 45.5% 59.3% 52.7% 
2 Slightly sad 42.9% 28.6% 30.6% 47.3% 33.3% 38.2% 
3. Moderately sad 6.1% 10.2% 10.2% 7.3% 7.4% 7.3% 
4. Very sad 0.0% 2.0% 2.0% 0.0% 0.0% 1.8% 
5. Extremely sad 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 




Average level on the answers of the 15D questionnaire at 
baseline 
 Average level on the answers of the 15D questionnaire at baseline, both cancer groups and both 
intervention groups together. 
 Average level of answer Average total 














Usual activities 1.8 
Mental function 1.3 




Sexual activity 2.8 
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